1.

Pneumonia
Definition: Pneumonia is an acute inflammatory condition of the lung parenchyma (alveoli
and bronchioles) caused by an infection (bacteria, viruses, fungi, or other microorganisms)
or inhalation of irritating substances. It results in the alveoli filling with fluid or pus, making
breathing difficult and impairing oxygen exchange.

Clinical Manifestations:

●​ Respiratory: Cough (productive with yellow/green/bloody sputum or dry), dyspnea

(shortness of breath), tachypnea (rapid breathing), pleuritic chest pain (sharp pain
with breathing/coughing), crackles/rales on auscultation, decreased breath
sounds, dullness to percussion.
●​ Systemic: Fever, chills, rigors, fatigue, malaise, myalgia, headache, loss of appetite,
sweating, rapid heart rate (tachycardia).
●​ Atypical/Severe: Confusion (especially in older adults), nausea, vomiting, diarrhea,
abdominal pain, cyanosis (bluish skin/lips/nails), respiratory distress, acute
respiratory distress syndrome (ARDS).
●​ In infants/young children: May have subtle symptoms like grunting, noisy
breathing, decreased urine output, pallor, limpness, increased fussiness, difficulty
feeding.

Medical Management:

●​ Antibiotics: For bacterial pneumonia (e.g., amoxicillin, macrolides,

fluoroquinolones). Choice depends on suspected pathogen, severity, and local
resistance patterns.
●​ Antivirals: For viral pneumonia (e.g., oseltamivir for influenza-related pneumonia),
though often supportive care is primary.
●​ Antifungals: For fungal pneumonia.
●​ Supportive Care:
○​ Oxygen therapy: To maintain adequate oxygen saturation.
○​ Fluid management: Hydration to thin secretions and prevent dehydration.
○​ Antipyretics: For fever (e.g., acetaminophen, NSAIDs).
○​ Cough suppressants/Expectorants: Judiciously used, depending on cough
type and sputum production.
○​ Bronchodilators: If bronchospasm is present.
○​ Mechanical ventilation: For severe respiratory failure (ARDS).
●​ Hospitalization: Recommended for severe cases, immunocompromised individuals,
older adults, and those with significant comorbidities.

Risk Factors:

●​ Age: Very young children (under 2 years) and older adults (over 65 years).
●​ Immunocompromised status: HIV/AIDS, cancer, organ transplant recipients,
chemotherapy, chronic steroid use.
 ●​ Chronic medical conditions: COPD, asthma, heart failure, diabetes, kidney
disease, liver disease.
●​ Lifestyle factors: Smoking, alcohol abuse, IV drug use.
●​ Environmental/Occupational: Exposure to pollutants, certain chemicals.
●​ Aspiration risk: Dysphagia, altered mental status, stroke, GERD.
●​ Hospitalization/Ventilation: Hospital-acquired pneumonia (HAP),
ventilator-associated pneumonia (VAP).
●​ Lack of vaccination: Pneumococcal, influenza, Haemophilus influenzae type b (Hib)
vaccines.

Diagnostic Test:

●​ Chest X-ray (CXR): "Gold standard" for identifying lung infiltrates/consolidation.

CT scan may be used for better visualization or if CXR is inconclusive.
●​ Sputum culture and Gram stain: To identify bacterial pathogen and guide antibiotic
choice.
●​ Blood cultures: To detect bacteremia.
●​ Complete Blood Count (CBC): May show leukocytosis (elevated white blood
cell count) in bacterial pneumonia.
●​ Arterial Blood Gases (ABGs): To assess oxygenation and acid-base balance.
●​ Rapid diagnostic tests: For viral pathogens (e.g., influenza, RSV).
●​ Bronchoscopy with bronchoalveolar lavage (BAL): For immunocompromised
patients or when initial diagnostics are inconclusive.
●​ Urine antigen tests: For Streptococcus pneumoniae and Legionella pneumophila.

Surgical Management:

●​ Rarely needed. May include:

○​ Thoracentesis: To drain significant pleural effusions.
○​ Chest tube insertion: For empyema (pus in the pleural space).
○​ Decortication: Surgical removal of thick fibrous peel from the lung surface in
chronic empyema.
○​ Lung abscess drainage: In rare, complicated cases.

Pathophysiology:

1.​ Inhalation/Aspiration: Pathogens enter the respiratory tract.

2.​ Overwhelm Defense Mechanisms: If the immune system (mucociliary escalator,
alveolar macrophages) is overwhelmed, pathogens multiply in the alveoli.
3.​ Inflammatory Response: The host immune response is triggered, leading to an
influx of inflammatory cells (neutrophils, macrophages) and fluid into the alveolar
space.
4.​ Consolidation: This fluid and cellular exudate fills the alveoli, leading to
consolidation, impairing gas exchange.
5.​ Stages of Inflammation:
○​ Congestion: Lungs appear heavy and boggy, vascular engorgement,
alveolar fluid rich in organisms.
○​ Red Hepatization: Alveoli fill with RBCs, neutrophils, and fibrin; lung
becomes red and firm.
 ○​ Gray Hepatization: RBCs break down, fibrin and neutrophils persist; lung
appears gray.
○​ Resolution: Macrophages clear cellular debris, and lung tissue returns to
normal.

Nursing Diagnoses:

●​ Impaired Gas Exchange related to alveolar-capillary membrane changes and fluid

accumulation.
●​ Ineffective Airway Clearance related to increased tracheobronchial secretions and
ineffective cough.
●​ Ineffective Breathing Pattern related to inflammation and chest pain.
●​ Activity Intolerance related to hypoxemia and fatigue.
●​ Acute Pain related to pleuritic inflammation.
●​ Hyperthermia related to the infectious process.
●​ Deficient Knowledge regarding the disease process and treatment.
●​ Risk for Fluid Volume Deficit related to fever and increased metabolic rate.

Nursing Interventions:

●​ Respiratory Management:
○​ Administer oxygen as prescribed, monitor SaO2.
○​ Encourage deep breathing and coughing exercises.
○​ Assist with incentive spirometry.
○​ Position patient for optimal lung expansion (e.g., semi-Fowler's).
○​ Perform chest physiotherapy (percussion, vibration, postural drainage) if
indicated.
○​ Suction airways as needed.
○​ Encourage adequate hydration to thin secretions.
●​ Medication Administration: Administer antibiotics, antivirals, antifungals,
antipyretics, and bronchodilators as ordered. Monitor for effectiveness and side
effects.
●​ Pain Management: Administer analgesics for chest pain; splint chest when
coughing.
●​ Fluid and Nutrition:
○​ Monitor intake and output.
○​ Provide intravenous fluids if necessary.
○​ Offer small, frequent, high-calorie, high-protein meals once tolerated.
●​ Activity and Rest:
○​ Balance rest with activity to prevent fatigue and promote recovery.
○​ Assist with ambulation as tolerated.
●​ Infection Control:
○​ Implement standard precautions.
○​ Proper hand hygiene.
○​ Ensure proper disposal of respiratory secretions.
●​ Patient Education:
○​ Explain the disease process and treatment plan.
○​ Emphasize importance of completing antibiotic course.
 ○​ Teach signs and symptoms of worsening condition.
○​ Discuss smoking cessation and vaccination (influenza, pneumococcal).
○​ Promote good hygiene to prevent spread.

2. Tuberculosis (TB)
Definition: Tuberculosis is a chronic, infectious disease caused by the bacterium
Mycobacterium tuberculosis (M. tuberculosis). It primarily affects the lungs (pulmonary TB)
but can spread to other parts of the body (extrapulmonary TB), including the kidneys, spine,
brain, lymph nodes, and bones.

Clinical Manifestations:

●​ Pulmonary TB (Active):
○​ Persistent cough: Lasting 3 weeks or longer, often productive (sputum,
sometimes blood-tinged/hemoptysis).
○​ Chest pain.
○​ Fatigue/weakness.
○​ Weight loss and anorexia.
○​ Fever.
○​ Night sweats.
○​ Chills.
●​ Extrapulmonary TB: Symptoms vary depending on the affected organ (e.g.,
swollen lymph nodes, back pain, joint pain, confusion, headache, abdominal pain).
●​ Latent TB Infection (LTBI): No symptoms, but the bacteria are present in the body.
Not contagious.

Medical Management:

●​ Antitubercular Drugs (First-line for drug-sensitive TB): A multi-drug regimen is

crucial to prevent drug resistance and ensure effective treatment.
○​ Intensive Phase (2 months): Isoniazid (INH), Rifampin (RIF), Pyrazinamide
(PZA), Ethambutol (EMB). (RIPE)
○​ Continuation Phase (4-7 months): INH and RIF. (RI)
●​ Drug-Resistant TB (MDR-TB, XDR-TB): Requires longer treatment with second-line
drugs (e.g., fluoroquinolones, injectable agents like amikacin, capreomycin,
bedaquiline, delamanid), which have more side effects.
●​ Directly Observed Therapy (DOT): Highly recommended, where a healthcare
worker observes the patient taking their medication to ensure adherence.
●​ Supportive Care:
○​ Nutrition support to combat weight loss.
○​ Symptomatic treatment for fever, pain.
○​ Management of drug side effects.
Risk Factors:

●​ Close contact with an active TB patient.

●​ Immunocompromised status: HIV/AIDS (highest risk), diabetes, chronic kidney
disease, organ transplants, cancer, malnutrition, prolonged corticosteroid use.
●​ Geography: Born in or traveled to countries with high TB rates (e.g., parts of Asia,
Africa, Eastern Europe).
●​ Socioeconomic factors: Poverty, homelessness, crowded living conditions (e.g.,
correctional facilities, shelters).
●​ Substance abuse: IV drug use, alcoholism.
●​ Healthcare workers: Increased exposure risk.
●​ Infants and young children.

Diagnostic Test:

●​ Tuberculin Skin Test (TST) / Mantoux test: For screening, detects M. tuberculosis
infection (latent or active). A positive result indicates exposure, not necessarily
active disease.
●​ Interferon-Gamma Release Assays (IGRAs): (e.g., QuantiFERON-TB Gold,
[Link]) Blood tests that detect M. tuberculosis infection, generally more specific
than TST.
●​ Chest X-ray (CXR): To detect lung infiltrates, cavitations, or other abnormalities
suggestive of active pulmonary TB.
●​ Sputum smear microscopy (Acid-Fast Bacilli - AFB smear): Rapid detection of
TB bacilli in sputum.
●​ Sputum culture (for M. tuberculosis): Gold standard for confirming active TB
and for drug susceptibility testing. Takes several weeks.
●​ Nucleic Acid Amplification Tests (NAATs): (e.g., GeneXpert MTB/RIF) Rapid
molecular tests that detect M. tuberculosis DNA and resistance to rifampin directly
from sputum.
●​ Biopsy: For extrapulmonary TB (e.g., lymph node biopsy, pleural biopsy).

Surgical Management:

●​ Rarely performed, primarily for complications of pulmonary TB or certain

extrapulmonary forms.
○​ Pneumonectomy/Lobectomy: To remove severely damaged lung tissue or
persistent cavities, especially in drug-resistant cases.
○​ Drainage of abscesses: For localized collections of pus.
○​ Debridement/fusion: For spinal TB (Pott's disease).

Pathophysiology:

1.​ Inhalation: M. tuberculosis enters the lungs via airborne droplets.

2.​ Alveolar Macrophage Phagocytosis: Bacilli are engulfed by alveolar macrophages
but are not destroyed due to their unique cell wall.
3.​ Primary Infection (Ghon Focus): Macrophages transport bacilli to regional lymph
nodes, leading to a localized inflammatory response and formation of a granuloma
(Ghon focus).
 4.​ Latent TB Infection (LTBI): In immunocompetent individuals, the immune system
walls off the bacilli within the granuloma, preventing active replication. The person is
infected but asymptomatic and not contagious. The granuloma can calcify (Ranke
complex).
5.​ Reactivation/Active TB Disease: If the host's immune system becomes
compromised (e.g., HIV, malnutrition, old age), the bacilli can reactivate, multiply, and
break out of the granuloma. This leads to tissue destruction, cavitation (especially in
upper lung lobes due to higher oxygen tension), and active disease.
6.​ Dissemination: Bacilli can spread via lymphatic system or bloodstream to other
organs, causing extrapulmonary TB.

Nursing Diagnoses:

●​ Ineffective Airway Clearance related to increased tracheobronchial secretions.

●​ Ineffective Breathing Pattern related to decreased lung capacity.
●​ Activity Intolerance related to fatigue and compromised respiratory function.
●​ Imbalanced Nutrition: Less Than Body Requirements related to anorexia, fatigue,
and increased metabolic demands.
●​ Risk for Infection Transmission related to airborne spread of M. tuberculosis.
●​ Deficient Knowledge regarding disease process, treatment regimen, and prevention
of spread.
●​ Social Isolation related to stigma and required isolation.

Nursing Interventions:

●​ Infection Control:
○​ Implement airborne precautions (negative pressure room, N95 respirators for
healthcare workers).
○​ Educate patient on respiratory hygiene and cough etiquette (cover
mouth/nose, dispose of tissues).
○​ Isolate patient until sputum smears are negative (usually after 2-3 weeks of
effective treatment).
●​ Medication Management:
○​ Administer antitubercular drugs as prescribed.
○​ Emphasize the importance of completing the entire course of medication,
even after symptoms improve, to prevent drug resistance and relapse.
○​ Monitor for side effects (e.g., hepatotoxicity, neuropathy, optic neuritis).
○​ Educate on DOT where applicable.
●​ Respiratory Support:
○​ Monitor respiratory status, breath sounds, oxygen saturation.
○​ Encourage deep breathing and coughing.
●​ Nutrition and Hydration:
○​ Provide high-calorie, high-protein diet.
○​ Encourage fluid intake.
○​ Monitor weight and nutritional status.
●​ Activity and Rest:
○​ Encourage rest during the acute phase.
○​ Gradually increase activity as tolerated.
 ●​ Psychosocial Support:
○​ Address patient's concerns about stigma and isolation.
○​ Provide emotional support.
●​ Patient and Family Education:
○​ Educate on the disease, transmission, treatment, and prevention.
○​ Explain the need for long-term therapy and follow-up.
○​ Screening of close contacts.

3. Severe Acute Respiratory Syndrome (SARS)

Definition: Severe Acute Respiratory Syndrome (SARS) is a viral respiratory illness caused
by the SARS-associated coronavirus (SARS-CoV-1). It first emerged in 2002-2003 and
caused a global outbreak. No cases have been reported since 2004. It is characterized by
severe pneumonia and can lead to acute respiratory distress syndrome (ARDS).

Clinical Manifestations:

●​ Early/Flu-like symptoms (2-7 days after exposure): Fever (often high, >38°C or
100.4°F), chills, rigors, headache, muscle aches (myalgia), lethargy, sore throat.
●​ Respiratory symptoms (after about a week): Dry cough, shortness of breath
(dyspnea), hypoxia.
●​ Gastrointestinal symptoms: Diarrhea, nausea, vomiting (less common but
reported).
●​ Progression: In some individuals, lung symptoms worsen in the second week, even
if fever subsides, leading to severe pneumonia and ARDS.

Medical Management:

●​ Supportive Care: The primary treatment for SARS, as it is a viral disease with no
specific antiviral drug proven effective.
○​ Oxygen therapy: To maintain oxygen saturation.
○​ Mechanical ventilation: For respiratory failure and ARDS.
○​ Fluid management.
○​ Antipyretics: For fever.
○​ Pain relievers: For muscle aches and headache.
●​ Antibiotics: May be given to treat or prevent secondary bacterial pneumonia.
●​ Corticosteroids: Use was controversial during the outbreak; some studies
suggested benefit in reducing inflammation, but others showed no clear benefit or
potential for harm. Not routinely recommended.
●​ Convalescent plasma: Explored as a treatment, but strong evidence of efficacy was
lacking.

Risk Factors:

●​ Close contact with an infected person: Most commonly spread through respiratory
droplets during coughing, sneezing, or talking.
 ●​ Healthcare workers: High risk due to direct patient contact.
●​ Household members: Living with an infected person.
●​ Travel to affected regions: During the 2002-2003 outbreak.
●​ Compromised immune system: Although it affected otherwise healthy individuals,
comorbidities may have influenced severity.

Diagnostic Test:

●​ Clinical suspicion: Based on symptoms and epidemiological links (travel history to

affected areas, close contact with a probable case).
●​ Chest X-ray (CXR) or CT scan: Show atypical pneumonia or features of ARDS.
●​ Reverse Transcriptase Polymerase Chain Reaction (RT-PCR): For detection of
SARS-CoV-1 RNA from respiratory secretions (nasopharyngeal swabs, sputum),
blood, or stool.
●​ Antibody tests (ELISA/immunofluorescence assays): To detect antibodies
against SARS-CoV-1, indicating past infection.
●​ Complete Blood Count (CBC): May show leukopenia, lymphopenia.
●​ Blood chemistry tests: To assess organ function (e.g., liver, kidney).

Surgical Management:

●​ None directly related to SARS treatment. Surgical interventions would only be for
complications, such as lung abscess drainage, if it occurred.

Pathophysiology:

1.​ Viral Entry: SARS-CoV-1 primarily targets respiratory epithelial cells, entering via the
ACE2 receptor.
2.​ Viral Replication: The virus replicates within these cells, causing direct cellular
damage.
3.​ Immune Over-response: The body's immune system mounts a vigorous
inflammatory response, leading to a "cytokine storm" in severe cases.
4.​ Alveolar Damage: This inflammation causes widespread alveolar damage, leading
to fluid leakage into the alveoli, destruction of pneumocytes, and formation of hyaline
membranes.
5.​ Impaired Gas Exchange: The accumulated fluid and debris impair oxygen diffusion,
leading to hypoxemia and respiratory failure (ARDS).
6.​ Extrapulmonary Involvement: While primarily respiratory, SARS-CoV-1 has been
found in other organs, explaining reported gastrointestinal or other systemic
symptoms.

Nursing Diagnoses:

●​ Impaired Gas Exchange related to alveolar-capillary membrane damage and fluid

accumulation.
●​ Ineffective Airway Clearance related to increased secretions and inflammatory
exudate.
●​ Ineffective Breathing Pattern related to respiratory muscle fatigue and hypoxemia.
●​ Risk for Infection Transmission related to airborne and droplet spread.
 ●​ Fear/Anxiety related to the severity of illness and isolation.
●​ Imbalanced Nutrition: Less Than Body Requirements related to anorexia, dyspnea,
and increased metabolic demands.

Nursing Interventions:

●​ Strict Isolation and Infection Control:

○​ Implement airborne and contact precautions (negative pressure room, N95
respirator, gown, gloves, eye protection).
○​ Strict hand hygiene.
○​ Limit visitor access.
○​ Proper disinfection of contaminated surfaces and equipment.
●​ Respiratory Support:
○​ Monitor respiratory rate, depth, effort, and oxygen saturation closely.
○​ Administer oxygen as ordered.
○​ Position for comfort and optimal lung expansion.
○​ Assist with secretion clearance (suctioning if necessary).
○​ Prepare for and assist with mechanical ventilation if respiratory failure
worsens.
●​ Fluid and Electrolyte Balance:
○​ Monitor I&O, fluid balance.
○​ Administer IV fluids as prescribed.
●​ Fever Management: Administer antipyretics, provide cooling measures.
●​ Nutritional Support: Provide nutritional support, potentially via enteral or parenteral
routes if oral intake is insufficient.
●​ Psychosocial Support:
○​ Address fear and anxiety.
○​ Explain procedures and rationale for isolation.
○​ Maintain communication with family, even if physical visits are restricted.
●​ Monitor for Complications: Watch for signs of ARDS, kidney failure, liver
dysfunction.

4. Middle East Respiratory Syndrome (MERS)

Definition: Middle East Respiratory Syndrome (MERS) is a severe respiratory illness
caused by the Middle East Respiratory Syndrome Coronavirus (MERS-CoV). It was first
identified in Saudi Arabia in 2012. MERS-CoV is a zoonotic virus, primarily circulating in
dromedary camels, with spillover events to humans. Human-to-human transmission primarily
occurs in close contacts and healthcare settings.

Clinical Manifestations:

●​ Common symptoms: Fever, cough (often non-productive), shortness of breath

(dyspnea).
●​ Gastrointestinal symptoms: Diarrhea, nausea, vomiting, abdominal pain (less
common but reported).
 ●​ Severe cases: Can rapidly progress to severe pneumonia, acute respiratory distress
syndrome (ARDS), kidney failure, septic shock, and death.
●​ Atypical/Asymptomatic: Some cases can be asymptomatic or present with mild
respiratory symptoms, especially in younger, healthy individuals.
●​ Hospitalized patients: Often have pre-existing medical conditions.

Medical Management:

●​ Supportive Care: No specific antiviral treatment for MERS-CoV. Management is

primarily supportive.
○​ Oxygen therapy: To manage hypoxemia.
○​ Mechanical ventilation: For respiratory failure and ARDS.
○​ Fluid and electrolyte management.
○​ Antipyretics: For fever.
○​ Vasopressors: For septic shock.
○​ Renal replacement therapy: For kidney failure.
●​ Antibiotics: To treat or prevent secondary bacterial infections.
●​ Investigational therapies: Various antiviral agents and immunomodulators have
been explored, but none have proven consistently effective.

Risk Factors:

●​ Direct or indirect contact with dromedary camels: Particularly in the Arabian

Peninsula.
●​ Consumption of raw camel milk or undercooked camel meat.
●​ Close contact with an infected person: Especially in healthcare settings (largest
outbreaks), family members, household contacts.
●​ Healthcare workers: High risk.
●​ Underlying medical conditions: Diabetes, chronic lung disease, chronic heart
disease, chronic kidney disease, cancer, immunocompromised states (increased risk
for severe illness).
●​ Age: Older adults are more susceptible to severe illness.

Diagnostic Test:

●​ Clinical suspicion: Based on symptoms and epidemiological history (travel to

Arabian Peninsula, contact with camels or confirmed MERS case).
●​ RT-PCR (Reverse Transcriptase Polymerase Chain Reaction): Gold standard for
diagnosis. Performed on respiratory specimens (nasopharyngeal swabs, sputum,
bronchoalveolar lavage fluid), with lower respiratory tract samples often having
higher viral loads.
●​ Chest X-ray or CT scan: To evaluate for pneumonia, interstitial infiltrates,
consolidation, or pleural effusions.
●​ Blood tests: May show leukopenia, lymphopenia, thrombocytopenia, elevated
lactate dehydrogenase.

Surgical Management:
 ●​ No direct surgical management for MERS-CoV infection. Interventions would be
limited to managing complications (e.g., chest tube for significant pleural effusion).

Pathophysiology:

1.​ Viral Entry: MERS-CoV primarily infects respiratory epithelial cells, entering via the
DPP4 receptor.
2.​ Replication and Cell Damage: The virus replicates, leading to direct cytopathic
effects on infected cells.
3.​ Immune Dysregulation: An exaggerated inflammatory response, including cytokine
release, contributes to widespread lung damage.
4.​ Pulmonary Manifestations: Leads to pneumonia, diffuse alveolar damage, and
ARDS, characterized by fluid accumulation in alveoli, impaired gas exchange, and
respiratory failure.
5.​ Extrapulmonary Effects: MERS-CoV can also infect extrapulmonary organs (e.g.,
kidneys, liver), contributing to multi-organ dysfunction (e.g., acute kidney injury,
hepatitis). The exact mechanisms for extrapulmonary involvement are still being
studied.

Nursing Diagnoses:

●​ Impaired Gas Exchange related to viral pneumonia and ARDS.

●​ Ineffective Airway Clearance related to increased secretions.
●​ Risk for Infection Transmission related to droplet and contact spread.
●​ Risk for Acute Kidney Injury related to severe illness and potential direct viral effects.
●​ Fear/Anxiety related to severe illness and isolation.
●​ Powerlessness related to uncertain prognosis.

Nursing Interventions:

●​ Rigorous Infection Control:

○​ Implement airborne and contact precautions (private room, N95 respirator,
gown, gloves, eye protection).
○​ Strict adherence to hand hygiene.
○​ Limit movement of the patient outside the room.
○​ Ensure proper cleaning and disinfection of patient environment.
○​ Educate all personnel on PPE use and infection control.
●​ Respiratory Monitoring and Support:
○​ Continuous monitoring of respiratory status, SpO2, and ABGs.
○​ Administer oxygen, high-flow nasal cannula, non-invasive ventilation, or
prepare for mechanical ventilation as needed.
○​ Position patient to optimize oxygenation (e.g., prone positioning for ARDS).
○​ Aggressive airway management and suctioning.
●​ Fluid and Hemodynamic Management:
●​ Monitor vital signs, fluid balance, and signs of shock.
○​ Administer IV fluids and vasopressors as ordered to maintain blood pressure.
●​ Renal and Organ Function Monitoring:
○​ Monitor urine output, creatinine, and BUN.
○​ Monitor liver enzymes.
 ●​ Psychosocial Support:
○​ Provide emotional support to the patient and family.
○​ Address concerns about isolation and prognosis.
●​ Patie nt and Family Education:
○​ Explain the disease, isolation precautions, and supportive care.
○​ Emphasize the importance of strict adherence to infection control measures.

5. Ebola Virus Disease (EVD)

Definition: Ebola Virus Disease (EVD), formerly known as Ebola hemorrhagic fever, is a
rare but severe and often fatal illness in humans caused by infection with one of the Ebola
viruses (genus Orthoebolavirus, family Filoviridae). It is characterized by fever, severe
headache, muscle pain, weakness, fatigue, followed by vomiting, diarrhea, abdominal pain,
and sometimes unexplained bleeding.

Clinical Manifestations:

●​ Initial/Early symptoms (2-21 days after exposure, average 8-10 days): Sudden
onset of fever, severe headache, muscle pain, weakness, profound fatigue.
●​ Gastrointestinal symptoms (progressing): Vomiting, diarrhea (often profuse),
abdominal pain.
●​ Other symptoms: Sore throat, rash.
●​ Hemorrhagic manifestations (in about 50% of cases, later stage): Internal and
external bleeding (e.g., blood in vomit/feces, bleeding from gums, nose, eyes,
injection sites), petechiae, ecchymoses.
●​ Neurological symptoms: Confusion, irritability, aggression, seizures.
●​ Progression to severe illness: Can lead to shock, multi-organ failure (liver, kidney),
and widespread hemorrhage.

Medical Management:

●​ Aggressive Supportive Care: Crucial for improving survival, as there is no specific

cure for all Ebola virus species (though treatments exist for Ebola virus species).
○​ Fluid and electrolyte management: Aggressive intravenous fluid
resuscitation to combat severe dehydration from vomiting and diarrhea.
○​ Maintaining blood pressure: With fluids and vasopressors if needed.
○​ Oxygen therapy: To support respiratory function.
○​ Blood transfusions: To manage significant bleeding and maintain blood
counts.
○​ Pain management: For severe body aches and headache.
○​ Nutritional support.
○​ Treatment of co-infections: Malaria, typhoid.
●​ Specific Treatments (for Ebola virus species):
○​ Monoclonal antibodies: Inmazeb (atoltivimab, maftivimab, and odesivimab)
and Ebanga (ansuvimab) are approved treatments for EVD caused by Zaire
ebolavirus. These block the virus from entering cells. (MAB)
 ●​ Vaccination: ERVEBO (rVSV-ZEBOV) is an FDA-approved vaccine for prevention of
EVD caused by Zaire ebolavirus in individuals 18 years and older at potential risk of
exposure.

Risk Factors:

●​ Direct contact with blood, secretions, organs, or other body fluids of infected
animals: (e.g., fruit bats, chimpanzees, gorillas, monkeys, forest antelope,
porcupines) found ill or dead in rainforests.
●​ Direct contact with blood or body fluids of a person sick with or who has died
from Ebola: Through broken skin or mucous membranes.
●​ Contact with objects/surfaces contaminated with body fluids (e.g., needles,
bedding, clothing).
●​ Unsafe burial practices: Traditional burial ceremonies often involve direct contact
with the deceased.
●​ Sexual transmission: Virus can persist in semen for prolonged periods after
recovery.
●​ Healthcare workers: High risk due to direct contact with patients without adequate
personal protective equipment (PPE).
●​ Family members/caregivers: Caring for sick individuals.

Diagnostic Test:

●​ RT-PCR (Reverse Transcriptase Polymerase Chain Reaction): Primary and most

reliable diagnostic test, performed on blood samples. Detects viral RNA.
●​ Antibody-capture ELISA: To detect antibodies, indicating past or current infection.
●​ Antigen-capture detection tests: Detect viral proteins.
●​ Virus isolation by cell culture: Used for research and confirmation but takes longer.
●​ Blood tests: May show low white blood cell count (leukopenia), low platelet count
(thrombocytopenia), elevated liver enzymes, abnormal clotting factors.

Surgical Management:

●​ Not a primary treatment for EVD. Surgical interventions would only be for
complications, such as managing severe hemorrhage if it can be localized and
controlled.

Pathophysiology:

1.​ Viral Entry: Ebola virus enters the body through mucous membranes or broken skin.
2.​ Target Cells: It primarily targets and replicates in dendritic cells, monocytes,
macrophages, and endothelial cells.
3.​ Lymphatic and Systemic Spread: Infected immune cells carry the virus to regional
lymph nodes and then disseminate it throughout the body via the lymphatic system
and bloodstream.
4.​ Widespread Organ Infection: The virus infects a wide range of cells and organs,
particularly the liver, spleen, and adrenal glands.
 5.​ Endothelial Damage: Widespread infection of endothelial cells (lining blood vessels)
leads to increased vascular permeability, leakage of fluid into tissues, and
coagulopathy.
6.​ Immune Dysregulation and Cytokine Storm: The virus induces a strong,
uncontrolled inflammatory response, leading to a "cytokine storm" that further
damages tissues and organs.
7.​ Multi-organ Failure: Combined direct viral cytopathic effect, inflammatory response,
and coagulopathy result in severe internal bleeding, shock, and multi-organ failure
(e.g., acute kidney injury, liver failure, respiratory failure), which are often the cause
of death.

Nursing Diagnoses:

●​ Risk for Fluid Volume Deficit related to severe vomiting, diarrhea, and hemorrhage.
●​ Risk for Bleeding related to coagulopathy and platelet dysfunction.
●​ Impaired Tissue Integrity (Risk for Skin Breakdown) related to severe dehydration
and immobility.
●​ Risk for Infection Transmission related to highly contagious body fluids.
●​ Fear/Anxiety related to life-threatening illness, isolation, and unpredictable course.
●​ Acute Pain related to headache, myalgia, and abdominal pain.
●​ Imbalanced Nutrition: Less Than Body Requirements related to anorexia, vomiting,
and high metabolic demands.
●​ Social Isolation related to strict infection control measures.

Nursing Interventions:

●​ Extremely Rigorous Infection Control (Highest Priority):

○​ Strict Isolation: Patients must be cared for in designated isolation units with
highly trained staff.
○​ Full PPE: Healthcare workers must wear extensive PPE, including
impermeable gowns, multiple layers of gloves, N95 respirators or powered
air-purifying respirators (PAPRs), face shields, and boot covers. Strict donning
and doffing procedures are essential.
○​ Environmental Decontamination: Thorough and frequent disinfection of
surfaces with appropriate virucidal agents.
○​ Safe Handling of Waste: All waste (body fluids, contaminated materials)
must be handled as highly infectious biohazard waste and disposed of
according to strict protocols.
○​ Safe Burial Practices: Ensure safe and dignified burials of deceased
individuals, as bodies remain infectious.
●​ Fluid and Electrolyte Management:
○​ Aggressive IV fluid administration, monitoring for signs of fluid overload or
dehydration.
○​ Monitor electrolytes and correct imbalances.
○​ Monitor urine output closely.
●​ Hemodynamic Monitoring:
○​ Frequent vital sign assessment (BP, HR).
○​ Assess for signs of shock.
 ○​ Administer vasopressors as needed.
●​ Bleeding Management:
○​ Monitor for signs of internal or external bleeding.
○​ Administer blood products (packed red blood cells, platelets, fresh frozen
plasma) as ordered.
○​ Avoid unnecessary injections.
●​ Symptom Management:
○​ Administer antipyretics for fever, analgesics for pain, antiemetics for
nausea/vomiting, antidiarrheals.
●​ Nutritional Support: Provide small, frequent, easily digestible foods, or initiate
enteral/parenteral feeding.
●​ Psychosocial Support:
○​ Acknowledge the extreme fear and anxiety in patients and families.
○​ Provide clear, empathetic communication (even from behind PPE).
○​ Facilitate remote communication with family if possible.
●​ Monitoring for Complications: Close monitoring for ARDS, kidney failure, liver
failure, secondary infections, and neurological changes.

📖 Reviewer: Systemic Lupus

Erythematosus (SLE)
🔹 Definition
●​ Chronic, multisystem, autoimmune disease where the immune system produces
autoantibodies that attack healthy tissues.​

●​ Characterized by periods of exacerbations and remissions.​

●​ More common in women of childbearing age (15–45 years).​

🔹 Risk Factors
●​ Gender: Female (9:1 ratio vs males)​

●​ Genetic predisposition (family history of autoimmune diseases)​

●​ Ethnicity: Higher prevalence in African-American, Hispanic, Native American, and

Asian populations​

●​ Environmental triggers: Sunlight (UV), infections, stress​

●​ Drugs: Hydralazine, procainamide, isoniazid (drug-induced lupus)​

 ●​ Hormonal: Estrogen influence​

🔹 Pathophysiology
1.​ Genetic + environmental trigger → abnormal immune response.​

2.​ Production of autoantibodies (e.g., antinuclear antibody [ANA], anti-dsDNA,

anti-Smith).​

3.​ Formation of immune complexes → deposited in tissues.​

4.​ Causes inflammation and organ damage (skin, joints, kidneys, heart, lungs, CNS).

🔹 Clinical Manifestations (Variable & Systemic)

●​ Skin: Butterfly (malar) rash, discoid rash, photosensitivity, alopecia.​

●​ Musculoskeletal: Polyarthritis, joint pain, stiffness, swelling.​

●​ Renal: Lupus nephritis (proteinuria, hematuria)

●​ Cardiac: Pericarditis, myocarditis, endocarditis.​

●​ Respiratory: Pleuritis, pleural effusion.​

●​ Neurologic: Seizures, psychosis, neuropathy, cognitive dysfunction.​

●​ Hematologic: Anemia, leukopenia, thrombocytopenia.​

●​ General: Fatigue, fever, weight loss.​

🔹 Diagnostic Tests
●​ Positive Antinuclear Antibody (ANA) – most sensitive​

●​ Anti-dsDNA, Anti-Smith antibodies – specific for SLE​

●​ CBC: anemia, leukopenia, thrombocytopenia​

●​ ESR, CRP: elevated (inflammation)​

●​ Urinalysis: proteinuria, hematuria (nephritis)​

●​ Complement levels (C3, C4): decreased​

●​ Biopsy (kidney, skin) for definitive organ involvement

🔹 Medical Management
●​ No cure → aim is to control symptoms and prevent organ damage.​

●​ NSAIDs: joint pain, inflammation.​

●​ Antimalarials (Hydroxychloroquine): skin & joint manifestations.​

●​ Corticosteroids: acute exacerbations, severe inflammation.​

●​ Immunosuppressants (Azathioprine, Cyclophosphamide, Methotrexate): severe

organ involvement.​

●​ Biologics (Belimumab, Rituximab): refractory cases.​

●​ Dialysis or kidney transplant for severe lupus nephritis.

🔹 Nursing Interventions
●​ Skin care: sunscreen, protective clothing, avoid sun exposure.​

●​ Rest & energy conservation: manage fatigue.​

●​ Monitor renal function: I&O, labs, BP.​

●​ Monitor cardiovascular status: chest pain, murmurs, arrhythmias.​

●​ Monitor for infection: due to immunosuppressive therapy.​

●​ Medication teaching: adherence, side effects (e.g., hydroxychloroquine → eye

exams).​

●​ Psychosocial support: coping with chronic illness.​

●​ Diet: balanced, low-sodium (if hypertension/renal), adequate calcium & vitamin D.​

●​ Pregnancy counseling: risk of miscarriage, neonatal lupus.

🔹 Complications
●​ Lupus nephritis → chronic kidney disease​

●​ Cardiovascular disease (pericarditis, CAD, hypertension)​

●​ CNS lupus (seizures, psychosis, stroke)​

●​ Increased risk of infection & malignancy (from immunosuppressants)​

🔹 NCLEX Mnemonics
SLE = LUPUS

●​ L: Lung issues (pleuritis, effusion)​

●​ U: Urinary (nephritis, proteinuria)​

●​ P: Photosensitivity / Psychosis​

●​ U: Ulcers in mouth / skin rash (malar)​

●​ S: Serositis (pericarditis, pleuritis)​

SOAP BRAIN MD (for clinical features):

●​ S: Serositis​

●​ O: Oral ulcers​

●​ A: Arthritis​

●​ P: Photosensitivity​

●​ B: Blood disorders​

●​ R: Renal involvement​

●​ A: ANA positive​

●​ I: Immunologic (anti-dsDNA, anti-Sm)​

●​ N: Neurologic (seizures, psychosis)​

●​ M: Malar rash​

●​ D: Discoid rash
📖 Reviewer: Hypersensitivity &
Immunoglobulins
🔹 Hypersensitivity Reactions (Types I–IV)
Type Mechanism Onset Examples Key Points /
Nursing Notes

Type I: IgE-mediated → Seconds to Anaphylaxis, - Airway priority

Immediate / Mast cells & minutes allergic rhinitis, (ABC)-
Anaphylactic basophils asthma, Administer
release urticaria, epinephrine IM
histamine food/drug for anaphylaxis-
allergy Antihistamines,
corticosteroids

Type II: IgG or IgM bind Minutes to Hemolytic - Stop

Cytotoxic to antigens on hours transfusion transfusion if
cell surface → reaction, reaction-
complement hemolytic Monitor for
activation → anemia, hemolysis
cell lysis Goodpasture (jaundice, dark
syndrome, Rh urine)- Give IV
incompatibility fluids, O₂,
(erythroblastosi corticosteroids
s fetalis)

Type III: Antigen–antibod Hours to weeks Systemic Lupus - Treat

Immune y complexes Erythematosus inflammation:
Complex-Medi deposit in (SLE), NSAIDs,
ated tissues → Rheumatoid corticosteroids-
inflammation & arthritis, Monitor renal
tissue damage Post-streptococ function-
cal Plasmapheresis
glomerulonephri may help
tis, Serum remove immune
sickness complexes

Type IV: T-cell mediated 24–72 hours Tuberculosis - Treat with

Delayed / (NOT skin test corticosteroids-
Cell-Mediated antibody-mediat (Mantoux), Avoid allergens
ed); release Contact (latex, nickel)-
dermatitis
(poison ivy,
 cytokines → latex), Supportive care
tissue damage Graft-versus-ho for skin irritation
st disease

🔹 Immunoglobulins (Antibodies)
Immunoglobulin Function Location / Features

IgG - Most abundant (75–80%)- Blood, extracellular fluid

Provides long-term
immunity after infection or
vaccination- Crosses the
placenta → provides
passive immunity to fetus

IgA - Protects mucosal Secretions, mucous

surfaces (respiratory, GI, membranes
GU tracts)- Found in
secretions: saliva, tears,
breast milk, mucus

IgM - First antibody produced Blood, lymph fluid

during infection- Largest
antibody- Effective in
agglutination and
complement activation

IgE - Involved in allergic Lungs, skin, mucous

reactions & parasitic membranes
infections- Binds to mast
cells & basophils → triggers
histamine release

IgD - Small amounts in serum- Surface of immature B cells

Functions mainly as B-cell
receptor (helps activate B
cells)
🔹 NCLEX Mnemonics
Hypersensitivity Types = ACID

●​ A: Anaphylaxis & Allergy (Type I)​

●​ C: Cytotoxic (Type II)​

●​ I: Immune complex (Type III)​

●​ D: Delayed (Type IV)​

Immunoglobulins = GAMED

●​ G = IgG → Greatest amount, Goes across placenta​

●​ A = IgA → At mucosal Areas​

●​ M = IgM → Massive size, Made first​

●​ E = IgE → Allergy, Eosinophils, parasites​

●​ D = IgD → Don’t know much (B-cell receptor)

📖 Reviewer: Rheumatoid Arthritis vs

Osteoarthritis vs Gouty Arthritis
🔹 Rheumatoid Arthritis (RA)
Definition

●​ Chronic, autoimmune inflammatory disease → attacks synovial joints → systemic

effects.​

●​ Progressive → causes deformity and disability.​

Risk Factors

●​ Women > men (2–3x)​

●​ Age 30–50 years​

●​ Genetic predisposition (HLA-DR4, HLA-DR1)​

●​ Smoking​
Pathophysiology​
Autoimmune response → immune complexes in synovial fluid → inflammation → pannus
formation → cartilage and bone destruction → joint deformities.

Clinical Manifestations

●​ Symmetrical joint pain, swelling, stiffness (esp. AM >1 hr)​

●​ Affects small joints (hands, wrists, feet)​

●​ Systemic: fatigue, fever, weight loss, anemia​

●​ Deformities: ulnar drift, swan-neck fingers, boutonnière deformity​

Diagnostics

●​ Positive Rheumatoid Factor (RF)​

●​ Anti-CCP antibodies (more specific)​

●​ Elevated ESR, CRP​

●​ X-ray: joint erosion​

Management

●​ DMARDs (Methotrexate, Leflunomide, Sulfasalazine) – slows progression​

●​ Biologics (Etanercept, Adalimumab)​

●​ Corticosteroids, NSAIDs for flares​

●​ Physical therapy, joint protection, splints​

●​ Surgery (synovectomy, joint replacement)​

Nursing Notes

●​ Encourage rest & energy conservation​

●​ Heat therapy for stiffness; cold for acute inflammation​

●​ Assistive devices to prevent joint strain​

●​ Monitor for infection (due to immunosuppressants)

🔹 Osteoarthritis (OA)
Definition

●​ Degenerative joint disease → breakdown of cartilage (wear & tear).​

●​ Most common form of arthritis.​

Risk Factors

●​ Older age (>50 years)​

●​ Obesity​

●​ Joint overuse / trauma​

●​ Genetic predisposition​

Pathophysiology​
Cartilage degeneration → loss of joint space → bone spurs (osteophytes) → pain &
stiffness.

Clinical Manifestations

●​ Asymmetrical joint involvement​

●​ Affects weight-bearing joints (knees, hips, spine, hands)​

●​ Morning stiffness <30 min, worse with activity, better with rest​

●​ Crepitus​

●​ Bony enlargements: Heberden’s nodes (DIP), Bouchard’s nodes (PIP)​

Diagnostics

●​ X-ray: joint space narrowing, osteophytes​

●​ Normal labs (no systemic inflammation)​

Management

●​ Weight reduction, exercise, PT​

●​ Analgesics: acetaminophen (first-line), NSAIDs​

●​ Intra-articular corticosteroid injections​

●​ Joint replacement (hip, knee) if severe​

Nursing Notes

●​ Encourage low-impact exercises (swimming, walking)​

●​ Heat therapy for stiffness​

●​ Assistive devices to reduce joint strain

🔹 Gouty Arthritis (Gout)

Definition

●​ Metabolic disorder → uric acid crystal deposition in joints → inflammation.​

Risk Factors

●​ Male > female​

●​ High purine diet (red meat, shellfish, alcohol, organ meats)​

●​ Obesity, HTN, diuretics, renal disease​

●​ Family history​

Pathophysiology​
Excess uric acid (overproduction or underexcretion) → monosodium urate crystals in
synovial fluid → intense inflammation.

Clinical Manifestations

●​ Sudden, severe pain (often big toe = podagra)​

●​ Redness, swelling, warmth of joint​

●​ Tophi (chronic gout – urate deposits in skin, ears, joints)​

●​ Kidney stones (uric acid nephrolithiasis)​

Diagnostics

●​ Serum uric acid ↑ (>6 mg/dL)​

●​ Joint aspiration: urate crystals (definitive)​

●​ X-ray: tophi, joint damage​

Management

●​ Acute attack: NSAIDs (indomethacin), colchicine, corticosteroids​

 ●​ Long-term: Allopurinol (xanthine oxidase inhibitor), Probenecid (uric acid
excretion)​

●​ Lifestyle: low-purine diet, avoid alcohol, hydration​

Nursing Notes

●​ Bed rest during acute attack​

●​ Elevate and protect joint​

●​ Encourage hydration (2–3 L/day)​

●​ Avoid foods high in purines (anchovies, sardines, organ meats, red meat, alcohol,
shellfish)

🔹 NCLEX Mnemonics
RA = 3 S’s

●​ S: Symmetrical​

●​ S: Small joints first​

●​ S: Systemic (fatigue, fever, anemia)

OA = O-A

●​ O: Older adults​

●​ A: Asymmetrical, Activity worsens pain

GOUT = GOUT

●​ G: Great toe pain​

●​ O: Onset sudden, Overproduction of uric acid​

●​ U: Uric acid ↑​

●​ T: Tophi, Tender joints​

📖 Reviewer: Diabetes Mellitus (Type 1
vs Type 2)
🔹 Definition
●​ Diabetes Mellitus (DM): Chronic metabolic disorder of impaired glucose
regulation due to defects in insulin secretion, insulin action, or both.​

●​ Leads to hyperglycemia → vascular & organ damage.​

🔹 Differences: Type 1 vs Type 2

Feature Type 1 Diabetes Type 2 Diabetes

Cause Autoimmune destruction of Insulin resistance +

pancreatic beta cells → no relative insulin deficiency
insulin

Onset Usually Usually adulthood (>40 yrs),

childhood/adolescence but rising in youth
(obesity-related)

Body type Lean, recent weight loss Overweight/obese,

metabolic syndrome

Insulin Absent → lifelong insulin Present but ineffective →

therapy required may need oral meds first,
then insulin later

Symptoms Classic 3 P’s: Polyuria, Gradual onset; fatigue,

Polydipsia, Polyphagia; recurrent infections, slow
weight loss, fatigue, blurred wound healing, acanthosis
vision nigricans

Ketoacidosis Common (DKA risk ↑) Rare (may develop HHS =

Hyperosmolar
Hyperglycemic State)
 Family history Less common Strong family link

Treatment Insulin only Lifestyle (diet, exercise),

Oral hypoglycemics, Insulin
(advanced)

🔹 Risk Factors
●​ Type 1: Genetics, autoimmune (HLA-DR3, DR4), viral infections (mumps, rubella,
coxsackie virus)​

●​ Type 2: Obesity, sedentary lifestyle, hypertension, dyslipidemia, age >40, family

history, ethnicity (African American, Hispanic, Asian, Native American)

🔹 Clinical Manifestations
●​ Both: Polyuria, polydipsia, polyphagia, fatigue, blurred vision, poor wound healing,
recurrent infections.​

●​ Type 1 specific: Sudden onset, weight loss, ketoacidosis risk.​

●​ Type 2 specific: Gradual onset, obesity, acanthosis nigricans, HHS risk.

🔹 Diagnostic Tests
●​ Fasting blood glucose ≥126 mg/dL​

●​ Random glucose ≥200 mg/dL with symptoms​

●​ HbA1c ≥6.5%​

●​ Oral Glucose Tolerance Test (OGTT): ≥200 mg/dL at 2 hrs​

●​ Urine: glucose, ketones (esp. Type 1)

🔹 Medical Management
Type 1:

●​ Insulin therapy (basal-bolus, pump)​

●​ Diet: consistent carb intake, avoid skipping meals​

●​ Exercise with careful monitoring (risk of hypoglycemia)

Type 2:

●​ Lifestyle modification (weight loss, diet, exercise)​

●​ Oral hypoglycemics:​

○​ Metformin (first-line, ↓ glucose production)​

○​ Sulfonylureas (stimulate insulin secretion)​

○​ DPP-4 inhibitors, GLP-1 agonists, SGLT2 inhibitors​

●​ Insulin (when oral meds are insufficient)

🔹 Nursing Interventions
●​ Monitor blood glucose (SMBG or continuous glucose monitor)​

●​ Teach hypoglycemia recognition: shakiness, sweating, confusion, headache,

tachycardia​

●​ Manage hypoglycemia: 15 g rapid sugar → recheck after 15 min (rule of 15)​

●​ Foot care: daily inspection, proper footwear, avoid barefoot walking​

●​ Encourage healthy lifestyle: balanced diet, exercise, weight control​

●​ Teach proper insulin administration (rotation of sites, storage)​

●​ Monitor for complications: neuropathy, nephropathy, retinopathy, cardiovascular

disease

🔹 Complications
●​ Acute:​

○​ Type 1: Diabetic Ketoacidosis (DKA)​

○​ Type 2: Hyperosmolar Hyperglycemic State (HHS)​

●​ Chronic (both):​

○​ Macrovascular: CAD, stroke, PVD​

○​ Microvascular: Retinopathy, nephropathy, neuropathy

🔹 NCLEX Mnemonics
Type 1 = “Juvenile, Insulin”

●​ 1 = One → needs insulin only​

 ●​ “Thin kids with ketones”

Type 2 = “Old & Overweight”

●​ “Two = Too much sugar, Too much weight”​

●​ Managed first with Tablets (oral meds)

Diabetes Signs = 3 P’s

●​ P: Polyuria​

●​ P: Polydipsia​

●​ P: Polyphagia

Hypoglycemia = TIRED

●​ T: Tachycardia​

●​ I: Irritability​

●​ R: Restlessness​

●​ E: Excessive hunger​

●​ D: Diaphoresis, Depression

📖 Reviewer: Pyelonephritis
🔹 Definition
●​ Pyelonephritis is a bacterial infection of the renal pelvis and kidney
parenchyma.​

●​ Usually starts as a lower urinary tract infection (cystitis) that ascends to the kidney.

🔹 Types
●​ Acute Pyelonephritis: sudden, severe infection → can lead to sepsis if untreated.​

●​ Chronic Pyelonephritis: recurrent or persistent infection → scarring, renal

dysfunction, and eventual chronic kidney disease.

🔹 Risk Factors
●​ Female (shorter urethra)​

●​ Vesicoureteral reflux (VUR)​

 ●​ Urinary tract obstruction (BPH, kidney stones)​

●​ Indwelling catheters​

●​ Diabetes mellitus​

●​ Pregnancy​

●​ Immunosuppression

🔹 Pathophysiology
1.​ Bacteria (commonly E. coli) ascend from bladder → ureter → kidney.​

2.​ Inflammatory response → infiltration by WBCs → kidney tissue edema.​

3.​ Repeated infections → scarring, loss of renal function (chronic form).

🔹 Clinical Manifestations
Acute Pyelonephritis

●​ Fever, chills​

●​ Flank pain (costovertebral angle tenderness)​

●​ Dysuria, urgency, frequency​

●​ Cloudy or foul-smelling urine​

●​ Nausea, vomiting, malaise

Chronic Pyelonephritis

●​ May be asymptomatic​

●​ Hypertension​

●​ Polyuria, nocturia​

●​ Progressive renal failure signs

🔹 Diagnostic Tests
●​ Urinalysis: pyuria (WBCs), bacteriuria, hematuria​

●​ Urine culture: identifies causative organism (often E. coli)​

●​ CBC: leukocytosis (↑ WBC count)​

●​ Blood culture: if sepsis suspected​

 ●​ Ultrasound/CT scan: detect obstruction, abscess, or stones​

●​ IVP (intravenous pyelogram): not first-line but shows structural abnormalities

🔹 Medical Management
●​ Antibiotics (first-line):​

○​ Mild/moderate: Oral fluoroquinolones (ciprofloxacin),

trimethoprim-sulfamethoxazole​

○​ Severe: IV antibiotics (ampicillin + gentamicin, ceftriaxone, or carbapenems)​

●​ Analgesics, antipyretics (acetaminophen)​

●​ IV fluids (to maintain hydration, flush bacteria)​

●​ Surgery if obstruction or stones present​

●​ Hospitalization if pregnant, septic, or severe illness

🔹 Nursing Interventions
●​ Monitor VS, especially temperature and BP (risk for sepsis, hypertension).​

●​ Encourage increased fluid intake (2–3 L/day) unless contraindicated.​

●​ Administer antibiotics as prescribed and monitor for side effects.​

●​ Promote frequent voiding to flush bacteria.​

●​ Educate patient: complete full course of antibiotics.​

●​ Teach preventive measures:​

○​ Proper perineal hygiene (wipe front to back)​

○​ Avoid prolonged catheterization​

○​ Urinate after sexual intercourse​

○​ Manage underlying conditions (DM, BPH, stones)

🔹 Complications
●​ Renal abscess​

●​ Urosepsis → septic shock​

●​ Chronic pyelonephritis → chronic kidney disease​

●​ Hypertension
🔹 NCLEX Mnemonic
PYELO

●​ P: Pain in flank, fever, chills​

●​ Y: You need fluids (increase hydration)​

●​ E: Elevated WBC & bacteria in urine​

●​ L: Look for costovertebral tenderness​

●​ O: Organism is usually E. coli

📖 Reviewer: Pneumonia
🔹 Definition
●​ Pneumonia is an infection and inflammation of the lung parenchyma (alveoli,
interstitial tissue, and/or bronchioles).​

●​ Causes the alveoli to fill with fluid or pus, impairing gas exchange.

🔹 Types
●​ Community-acquired pneumonia (CAP) – outside hospital setting​

●​ Hospital-acquired pneumonia (HAP) – ≥48 hrs after admission​

●​ Ventilator-associated pneumonia (VAP) – ≥48 hrs after intubation​

●​ Aspiration pneumonia – inhalation of food, liquid, gastric contents, or foreign

material​

●​ Opportunistic pneumonia – in immunocompromised (HIV/AIDS, chemotherapy,

transplant)

🔹 Risk Factors
●​ Age extremes (infants, elderly)​

●​ Smoking​

●​ Chronic illnesses (COPD, diabetes, CHF)​

●​ Immunosuppression (HIV, chemotherapy, steroids)​

●​ Postoperative state, immobility​

 ●​ Aspiration risk (stroke, dysphagia, NG tube, decreased LOC)​

●​ Poor nutrition, alcoholism

🔹 Pathophysiology
1.​ Pathogen (bacteria: Streptococcus pneumoniae most common; viruses, fungi,
aspiration) enters alveoli.​

2.​ Inflammatory response → alveolar-capillary membrane damage.​

3.​ Alveoli fill with exudate (fluid, WBCs, bacteria).​

4.​ ↓ Gas exchange → hypoxemia, dyspnea.​

5.​ Consolidation (lung tissue becomes firm/dense).

🔹 Clinical Manifestations
●​ Classic symptoms:​

○​ Fever, chills​

○​ Productive cough (rust-colored, purulent, or green sputum)​

○​ Dyspnea, tachypnea​

○​ Pleuritic chest pain​

●​ Physical exam findings:​

○​ Crackles, rhonchi, decreased breath sounds​

○​ Dullness to percussion​

○​ Increased tactile fremitus​

●​ Older adults: confusion, fatigue, anorexia (may lack fever/cough)

🔹 Diagnostic Tests
●​ Chest X-ray: consolidation, infiltrates​

●​ Sputum culture & sensitivity: identifies causative organism​

●​ Blood culture: if sepsis suspected​

●​ CBC: leukocytosis​

●​ Pulse oximetry / ABG: hypoxemia, respiratory alkalosis (early), acidosis (late)

🔹 Medical Management
●​ Antibiotics (if bacterial, based on culture) – e.g., ceftriaxone, azithromycin,
levofloxacin​

●​ Antivirals (if viral pneumonia, e.g., influenza A)​

●​ Antifungals (if fungal pneumonia, e.g., amphotericin B)​

●​ Supportive therapy:​

○​ Oxygen therapy (to correct hypoxemia)​

○​ Antipyretics (acetaminophen)​

○​ Analgesics (for pleuritic chest pain)​

○​ Hydration (thin secretions)​

○​ Bronchodilators, expectorants, mucolytics

🔹 Nursing Interventions
●​ Monitor VS, oxygen saturation, and respiratory status​

●​ Encourage coughing & deep breathing; incentive spirometry​

●​ Positioning: semi-Fowler’s or high-Fowler’s to improve ventilation​

●​ Maintain airway clearance: chest physiotherapy, suction if needed​

●​ Encourage fluids (2–3 L/day if not contraindicated)​

●​ Administer antibiotics/medications as prescribed​

●​ Provide rest and energy conservation​

●​ Educate on vaccines (pneumococcal, influenza), smoking cessation, and infection

prevention

🔹 Complications
●​ Pleural effusion​

●​ Lung abscess​

●​ Empyema (pus in pleural cavity)​

●​ Bacteremia → sepsis​

●​ Respiratory failure / ARDS

🔹 NCLEX Mnemonics
PNEUMONIA

●​ P: Productive cough, pleuritic pain​

●​ N: Neuro changes (confusion in elderly)​

●​ E: Elevated WBC, ESR​

●​ U: Unusual breath sounds (crackles, dullness)​

●​ M: Mild to high fever​

●​ O: Oxygen saturation low​

●​ N: Nausea, vomiting (sometimes)​

●​ I: Increased HR, RR​

●​ A: Aching, fatigue​

Priority Nursing Actions = AIR

●​ A: Airway (oxygen, suction PRN)​

●​ I: IV antibiotics & fluids​

●​ R: Respiratory support (positioning, incentive spirometry, chest PT)​

Tuberculosis (TB) Reviewer

Definition
●​ A chronic infectious disease caused by Mycobacterium tuberculosis.​

●​ Primarily affects the lungs (pulmonary TB) but can spread to other organs
(extrapulmonary TB: kidneys, bones, meninges, lymph nodes).​

●​ Spread through airborne droplets (coughing, sneezing, talking).​

Pathophysiology
1.​ Inhalation of M. tuberculosis → bacteria reach alveoli.​

2.​ Macrophages engulf bacteria but cannot destroy them → tubercle formation
(granuloma).​
 3.​ Granulomas may heal and calcify (Ghon’s focus) or progress to active disease.​

4.​ Active TB: tissue necrosis, cavitation, caseous necrosis → spreads via bronchi and
bloodstream.

Risk Factors
●​ Close contact with TB patient.​

●​ Immunocompromised (HIV/AIDS, cancer, steroid use).​

●​ Malnutrition, alcoholism, IV drug use.​

●​ Crowded living conditions, poverty, poor ventilation.​

●​ Health care workers.

Clinical Manifestations
●​ Early stages: asymptomatic or mild.​

●​ Pulmonary TB symptoms:​

○​ Persistent cough (>3 weeks).​

○​ Hemoptysis (bloody sputum).​

○​ Night sweats.​

○​ Fever, chills.​

○​ Fatigue, malaise.​

○​ Weight loss, anorexia ("consumption").​

○​ Chest pain, dyspnea (in advanced stages).

Diagnostic Tests
●​ Mantoux tuberculin skin test (TST/PPD)​

○​ Positive: induration ≥10 mm (≥5 mm in immunocompromised).​

○​ Does not confirm active TB, only exposure.​

●​ Interferon-Gamma Release Assays (IGRA) – blood test (Quantiferon-TB Gold).​

●​ Chest X-ray – shows infiltrates, cavitation, Ghon’s complex.​

●​ Sputum smear (AFB) – acid-fast bacilli staining.​

 ●​ Sputum culture – gold standard, confirms diagnosis.​

●​ NAAT (Nucleic Acid Amplification Test) – rapid confirmation.​

Medical Management
First-line Anti-TB Drugs (RIPE regimen)
●​ R – Rifampin (RIF): hepatotoxicity, red-orange urine/tears.​

●​ I – Isoniazid (INH): hepatotoxicity, peripheral neuropathy (prevent with Vitamin B6).​

●​ P – Pyrazinamide (PZA): hepatotoxicity, hyperuricemia (gout).​

●​ E – Ethambutol (EMB): optic neuritis (loss of red-green vision).​

👉 Treatment duration:
●​ 6–9 months (longer for resistant strains or immunocompromised patients).​

●​ DOT (Directly Observed Therapy) recommended by WHO.​

Nursing Interventions
●​ Place patient in airborne isolation (negative-pressure room, N95 respirator).​

●​ Teach cough etiquette and proper disposal of tissues.​

●​ Ensure adherence to long-term drug therapy.​

●​ Monitor for side effects of TB medications.​

●​ Encourage high-protein, high-calorie diet.​

●​ Promote rest and gradual activity increase.​

●​ Contact tracing and report to public health authorities.​

Complications
●​ Miliary TB (widespread dissemination).​

●​ TB meningitis.​

●​ Pott’s disease (TB of the spine → deformity).​

 ●​ Drug-resistant TB (MDR-TB, XDR-TB).​

●​ Respiratory failure.​

✅ NCLEX Tip Mnemonic for TB Drugs – "RIPE for Treatment"

●​ Rifampin – Red/orange fluids​

●​ Isoniazid – INH = Interferes with B6 → neuropathy​

●​ Pyrazinamide – Pain in joints (gout)​

●​ Ethambutol – Eye problems​

Ebola Virus Disease (EVD) Reviewer

Definition
●​ A severe, often fatal viral hemorrhagic fever caused by infection with Ebola virus,
a member of the Filoviridae family.​

●​ Mortality rate: 25–90%, depending on outbreak and management.​

●​ First discovered in 1976 near the Ebola River in the Democratic Republic of Congo.

Etiology
●​ Caused by Ebola virus (genus Ebolavirus), with several species:​

○​ Zaire ebolavirus (most deadly)​

○​ Sudan ebolavirus​

○​ Bundibugyo ebolavirus​

○​ Tai Forest ebolavirus​

○​ Reston ebolavirus (non-pathogenic to humans)

Mode of Transmission
●​ Zoonotic disease: reservoir believed to be fruit bats 🦇.​
●​ Human-to-human transmission via:​
 ○​ Direct contact with blood, secretions, or body fluids of infected persons.​

○​ Contact with contaminated surfaces/objects (e.g., needles, bedding).​

○​ Burial ceremonies involving direct contact with the body.​

●​ Not airborne, but droplets may spread through close contact.

Incubation Period
●​ 2–21 days (average: 8–10 days).​

●​ Patient is not contagious until symptoms appear.

Pathophysiology
1.​ Virus enters through mucous membranes, breaks in the skin, or parenterally.​

2.​ Infects monocytes, macrophages, dendritic cells → rapid viral replication.​

3.​ Release of pro-inflammatory cytokines → cytokine storm.​

4.​ Widespread vascular damage, impaired coagulation, and shock.​

5.​ Leads to multiorgan failure, hemorrhage, and death.

Clinical Manifestations
Early (non-specific, flu-like):

●​ Fever, chills, fatigue, headache, muscle aches​

●​ Sore throat, conjunctivitis

Progressive symptoms:

●​ Nausea, vomiting, diarrhea (often bloody)​

●​ Abdominal pain​

●​ Rash (maculopapular, non-itchy)

Severe/Late symptoms:

●​ Hemorrhagic signs: bleeding from gums, GI tract, puncture sites​

●​ Impaired liver and kidney function​

●​ Hypotension, shock, multi-organ failure

Diagnostic Tests
●​ RT-PCR – detects Ebola viral RNA (gold standard)​
 ●​ ELISA – detects Ebola antigens/antibodies​

●​ CBC: leukopenia, thrombocytopenia​

●​ LFT/KFT: elevated liver enzymes, renal impairment​

●​ Blood culture – to rule out bacterial infections

Medical Management
(No specific cure, treatment is supportive)

●​ Fluid & electrolyte replacement to prevent shock​

●​ Oxygen therapy for hypoxemia​

●​ Vasopressors for hypotension​

●​ Antipyretics & pain relief​

●​ Antiviral therapies (under research): Remdesivir, monoclonal antibodies (Inmazeb,

Ebanga)​

●​ Convalescent plasma (experimental)

Nursing Interventions
●​ Strict infection prevention & control (IPC):​

○​ PPE (gloves, gown, mask, eye protection)​

○​ Isolate suspected/confirmed cases​

○​ Proper disposal of sharps and contaminated materials​

●​ Hydration monitoring (IV fluids, oral rehydration if possible)​

●​ Monitor VS, I&O, electrolyte balance​

●​ Provide oxygen as needed​

●​ Psychological support to patient and family​

●​ Health teaching: avoid contact with body fluids, safe burial practices​

Risk Factors
●​ Health care workers without proper PPE​

●​ Family members caring for infected person​

 ●​ Burial rituals involving contact with body​

●​ Living near or handling fruit bats or primates

Complications
●​ Severe dehydration and hypovolemic shock​

●​ Disseminated intravascular coagulation (DIC)​

●​ Multi-organ failure​

●​ Secondary infections​

●​ High mortality rate

Prevention
●​ Avoid bushmeat & contact with bats/primates​

●​ Safe burial practices​

●​ Use PPE for healthcare workers​

●​ Surveillance & contact tracing​

●​ Vaccination: rVSV-ZEBOV (Ervebo) approved for Zaire Ebola virus

🦠 Middle East Respiratory Syndrome

(MERS)
📌 Definition
MERS is a viral respiratory illness caused by the Middle East Respiratory Syndrome
Coronavirus (MERS-CoV).

●​ First identified in Saudi Arabia, 2012​

●​ Belongs to the coronavirus family (same family as SARS and COVID-19).​

●​ Zoonotic disease → transmission from camels (reservoir host) to humans.

🧬 Pathophysiology
1.​ Transmission: Close contact with infected camels or humans.​

2.​ Viral Entry: MERS-CoV binds to DPP4 receptors on human cells (especially in the
lungs, kidneys, intestines).​
 3.​ Viral Replication → damages alveolar cells → inflammation.​

4.​ Immune Response → excessive cytokine release → severe pneumonia, ARDS,

septic shock, and multi-organ failure.​

⚠️ Risk Factors
●​ Contact with camels (farmers, slaughterhouse workers).​

●​ Health care workers exposed to MERS patients.​

●​ People with comorbidities (diabetes, chronic lung disease, renal disease,

immunocompromised).​

●​ Travelers or residents in the Middle East.

🩺 Clinical Manifestations
●​ Mild to Severe Respiratory Illness​

○​ Fever​

○​ Cough​

○​ Shortness of breath​

○​ Pneumonia-like symptoms​

●​ Gastrointestinal Symptoms​

○​ Diarrhea​

○​ Nausea, vomiting​

●​ Severe Cases​

○​ ARDS (acute respiratory distress syndrome)​

○​ Septic shock​

○​ Acute kidney injury​

○​ Death (high mortality rate: ~35–40%).

🔬 Diagnostic Tests
●​ RT-PCR → detects MERS-CoV RNA from respiratory samples.​

●​ Serology → antibody detection.​

 ●​ Chest X-ray/CT → bilateral infiltrates, pneumonia-like changes.​

●​ Blood tests → leukopenia, lymphopenia, elevated liver enzymes.

💊 Medical Management
⚠️ No specific antiviral treatment. Supportive care is mainstay.
●​ Supportive Care​

○​ Oxygen therapy, mechanical ventilation if needed.​

○​ IV fluids, electrolyte correction.​

○​ Renal replacement therapy (if kidney failure develops).​

●​ Experimental/Investigational Therapies​

○​ Antiviral drugs (ribavirin, interferon – limited success).​

○​ Monoclonal antibodies (still under study).​

●​ Prevention of complications: Treat pneumonia, sepsis, ARDS.​

🛡️ Prevention & Control

●​ Avoid direct contact with camels & camel products (raw milk, undercooked meat).​

●​ Hand hygiene & respiratory etiquette.​

●​ Use of PPE (masks, gowns, gloves) in healthcare settings.​

●​ Isolation of suspected/confirmed patients.​

●​ Strict infection control measures in hospitals (airborne, droplet, contact precautions).​

👩‍⚕️ Nursing Interventions

●​ Place patient on airborne & contact precautions.​

●​ Monitor respiratory status (O₂ sat, ABGs).​

●​ Administer oxygen or prepare for mechanical ventilation.​

●​ Provide IV fluids & electrolyte balance.​

●​ Monitor for complications (ARDS, kidney failure, septic shock).​

●​ Provide psychological support to patient & family.​

 ●​ Educate about infection prevention (hand hygiene, PPE, safe food handling).

✅M →Quick Mnemonic – MERS​

Monitor for respiratory distress​
E → Ensure isolation & PPE​
R → Respiratory support (oxygen, ventilation)​
S → Supportive care & surveillance for complications

🦠 Severe Acute Respiratory Syndrome

(SARS)
📌 Definition
●​ A viral respiratory illness caused by the SARS-associated coronavirus
(SARS-CoV), first identified in 2003.​

●​ It is a zoonotic disease that spread from animals (civets/bats) to humans.​

●​ Characterized by severe pneumonia-like symptoms with high risk of respiratory

failure.

🧬 Pathophysiology
1.​ Transmission: Primarily via respiratory droplets, close contact, and contaminated
surfaces.​

2.​ Viral entry: SARS-CoV binds to ACE2 receptors in respiratory tract epithelial cells.​

3.​ Replication: Virus replicates, causing cytopathic damage to alveolar cells.​

4.​ Immune response: Overactivation → cytokine storm, leading to severe lung

inflammation.​

5.​ Complication: Diffuse alveolar damage → Acute Respiratory Distress Syndrome

(ARDS) → respiratory failure.

⚠️ Risk Factors
●​ Healthcare workers (hospital outbreaks)​

●​ Close contact with SARS patients​

●​ Travel to endemic areas during outbreak​

●​ Elderly & immunocompromised individuals

🩺 Clinical Manifestations
●​ Incubation period: 2–10 days​
 ●​ Early symptoms (flu-like):​

○​ High fever (>38°C)​

○​ Chills, rigors​

○​ Headache, malaise, myalgia​

●​ Respiratory symptoms:​

○​ Dry cough (progressive)​

○​ Dyspnea​

○​ Hypoxemia​

○​ Possible progression to pneumonia within 7 days​

●​ Severe cases: ARDS, multi-organ failure

🔬 Diagnostic Tests
●​ History & travel/contact tracing (very important)​

●​ Chest X-ray / CT scan → bilateral infiltrates, pneumonia​

●​ RT-PCR (nasopharyngeal or oropharyngeal swab) → detects SARS-CoV RNA​

●​ Serology → detects SARS-CoV antibodies​

●​ CBC → leukopenia, lymphopenia, thrombocytopenia​

●​ Blood chemistry → elevated liver enzymes, LDH, CK

💊 Medical Management
Currently, no specific antiviral treatment proven effective. Management is supportive:

●​ Oxygen therapy (to prevent hypoxemia)​

●​ Mechanical ventilation for respiratory failure​

●​ Broad-spectrum antibiotics (if bacterial co-infection suspected)​

●​ Corticosteroids (controversial, may reduce inflammation)​

●​ Antiviral agents (ribavirin, interferons – limited effectiveness in trials)

🏥 Nursing Interventions
●​ Implement strict isolation precautions (airborne, droplet, and contact).​

●​ Use N95 respirators, gowns, gloves, and eye protection.​

 ●​ Monitor vital signs, O2 saturation, and respiratory status.​

●​ Encourage bed rest, hydration, and adequate nutrition.​

●​ Provide emotional support (patients often isolated).​

●​ Educate patient/family about infection prevention.​

●​ Report suspected cases immediately to health authorities.

🚫 Prevention
●​ No approved vaccine for SARS (different from COVID-19).​

●​ Standard precautions:​

○​ Frequent handwashing​

○​ Respiratory hygiene (cover coughs, masks)​

○​ Avoid close contact with sick individuals​

○​ Quarantine & contact tracing during outbreaks

✅SARS
Key Point for NCLEX/Board Exams:​
is a coronavirus-induced viral pneumonia with rapid progression to respiratory
distress, requires early isolation, strict PPE use, and supportive care.

COVID-19 (Coronavirus Disease 2019)

Reviewer
Definition
●​ A viral respiratory illness caused by the novel coronavirus SARS-CoV-2, first
identified in Wuhan, China in December 2019.​

●​ Declared a pandemic by the WHO on March 11, 2020.

Pathophysiology
1.​ SARS-CoV-2 enters the body via respiratory droplets, aerosols, or contaminated
surfaces.​

2.​ Virus binds to ACE2 receptors (angiotensin-converting enzyme 2) in the lungs,

heart, kidneys, intestines.​

3.​ Viral replication causes:​

○​ Cytokine release → “cytokine storm” → widespread inflammation.​

 ○​ Alveolar damage → impaired gas exchange → ARDS (acute respiratory
distress syndrome).​

○​ Potential multi-organ involvement.

Modes of Transmission
●​ Person-to-person via respiratory droplets (coughing, sneezing, talking).​

●​ Airborne transmission (in poorly ventilated spaces).​

●​ Fomites (contaminated surfaces).​

●​ Close contact without proper PPE.

Clinical Manifestations
●​ Mild/Moderate (most cases):​

○​ Fever, dry cough, fatigue​

○​ Sore throat, myalgia, headache​

○​ Loss of taste (ageusia) or smell (anosmia)​

○​ GI: diarrhea, nausea, abdominal pain​

●​ Severe:​

○​ Dyspnea, hypoxia​

○​ Chest pain/pressure​

○​ Confusion​

○​ Cyanosis​

●​ Complications:​

○​ Pneumonia​

○​ ARDS​

○​ Septic shock​

○​ Thromboembolic events (DVT, PE, stroke)​

○​ Multi-organ failure

Risk Factors
 ●​ Older age (>60 years)​

●​ Chronic illnesses:​

○​ Diabetes mellitus​

○​ Hypertension​

○​ Cardiovascular disease​

○​ COPD, asthma​

○​ Chronic kidney disease​

○​ Immunocompromised patients​

●​ Obesity, smoking​

Diagnostic Tests
●​ RT-PCR (gold standard): detects viral RNA​

●​ Antigen tests: rapid detection, less sensitive​

●​ Chest X-ray/CT scan: ground-glass opacities, bilateral infiltrates​

●​ Blood tests: elevated CRP, ferritin, D-dimer, lymphopenia

Medical Management
●​ Supportive care:​

○​ Oxygen therapy​

○​ IV fluids​

○​ Antipyretics (paracetamol)​

●​ Antivirals:​

○​ Remdesivir (FDA-approved for hospitalized patients)​

●​ Anti-inflammatory / immune-modulating:​

○​ Dexamethasone (for severe cases)​

○​ Tocilizumab (IL-6 inhibitor in cytokine storm)​

●​ Anticoagulants: for clot prevention​

 ●​ Ventilatory support:​

○​ High-flow oxygen​

○​ Mechanical ventilation (if severe ARDS)

Surgical Management
●​ None specific to COVID-19.​

●​ Tracheostomy may be considered for prolonged ventilation.​

Nursing Interventions
●​ Implement standard, contact, and airborne precautions (N95 mask, face shield,
gown, gloves).​

●​ Monitor vital signs, oxygen saturation.​

●​ Administer oxygen therapy as prescribed.​

●​ Ensure hydration and nutrition.​

●​ Encourage positioning (prone positioning) to improve oxygenation.​

●​ Provide psychological support (due to isolation, fear, stigma).​

●​ Educate on infection control: handwashing, mask use, physical distancing.​

●​ Report and document any deterioration promptly.​

Prevention
●​ Vaccination (Pfizer, Moderna, AstraZeneca, etc.)​

●​ Wearing masks​

●​ Frequent hand hygiene​

●​ Social distancing​

●​ Isolation of infected individuals​

●​ Adequate ventilation​

HIV / AIDS Reviewer

Definition
●​ HIV (Human Immunodeficiency Virus): A retrovirus that attacks the immune
system, specifically CD4+ T lymphocytes, leading to immunosuppression.​

●​ AIDS (Acquired Immunodeficiency Syndrome): The end-stage of HIV infection,

characterized by profound immunodeficiency and opportunistic infections/cancers.​

Pathophysiology
1.​ Transmission: blood, sexual contact, perinatal (in utero, delivery, breastfeeding).​

2.​ Viral entry: HIV binds to CD4 receptors + CCR5/CXCR4 co-receptors on T-helper
cells.​

3.​ Replication: reverse transcriptase converts viral RNA → DNA, integrates into host
genome.​

4.​ Immune destruction: progressive loss of CD4+ T cells → decreased immune

response.​

5.​ AIDS diagnosis: CD4 count <200 cells/mm³ or presence of AIDS-defining illness
(e.g., Pneumocystis pneumonia, Kaposi sarcoma).​

Risk Factors
●​ Unprotected sexual intercourse (anal > vaginal > oral)​

●​ Multiple sexual partners​

●​ Blood transfusion (esp. pre-1985, before screening)​

●​ IV drug use, needle sharing​

●​ Infants of HIV-positive mothers (vertical transmission)​

●​ Health care workers (needle-stick injuries)​

Clinical Manifestations
Acute HIV infection (2–4 weeks post exposure):
●​ Flu-like symptoms: fever, lymphadenopathy, sore throat, rash, myalgia, night sweats.​

Chronic HIV infection (asymptomatic stage):

 ●​ May last 8–10 years with gradual CD4 decline.​

●​ Persistent generalized lymphadenopathy, weight loss, recurrent infections.​

AIDS (advanced stage):

●​ Opportunistic infections: TB, candidiasis, Pneumocystis jiroveci pneumonia (PCP).​

●​ Opportunistic cancers: Kaposi’s sarcoma, non-Hodgkin’s lymphoma, cervical cancer.​

●​ Neurologic complications: HIV encephalopathy, peripheral neuropathy.​

Diagnostic Tests
●​ Screening:​

○​ ELISA (enzyme-linked immunosorbent assay) – detects HIV antibodies.​

○​ Rapid antibody tests.​

●​ Confirmation:​

○​ Western blot or HIV differentiation immunoassay.​

●​ Monitoring:​

○​ CD4+ T-cell count (normal: 500–1600; AIDS: <200).​

○​ HIV viral load (measures treatment response).​

Medical Management
●​ No cure, but Antiretroviral Therapy (ART/HAART) suppresses viral replication.​

●​ Classes of ART:​

○​ NRTIs (e.g., zidovudine, lamivudine)​

○​ NNRTIs (e.g., efavirenz, nevirapine)​

○​ Protease inhibitors (e.g., indinavir, ritonavir)​

○​ Integrase inhibitors (e.g., raltegravir)​

○​ Entry inhibitors (e.g., maraviroc, enfuvirtide)​

●​ Prophylaxis for opportunistic infections:​

○​ TMP-SMX (Bactrim) for Pneumocystis jiroveci pneumonia when CD4 <200.​

 ○​ Azithromycin/clarithromycin for Mycobacterium avium complex when CD4
<50.​

Nursing Interventions
●​ Promote adherence to ART.​

●​ Monitor for side effects (GI upset, lipodystrophy, hepatotoxicity, bone marrow
suppression).​

●​ Provide infection prevention teaching:​

○​ Handwashing, safe food/water, avoid sick contacts.​

○​ Vaccinations (influenza, pneumococcal, hepatitis B).​

●​ Nutritional support: high-protein, high-calorie diet.​

●​ Psychosocial support: address stigma, mental health, support groups.​

●​ Education on transmission prevention: safe sex practices, needle safety.

Complications
●​ Opportunistic infections (PCP, TB, toxoplasmosis, cryptococcal meningitis).​

●​ Malignancies (Kaposi sarcoma, lymphoma).​

●​ Neurological disorders (HIV dementia, neuropathy).​

●​ Wasting syndrome (severe weight loss, muscle atrophy).​

✅ NCLEX Tip: Remember the AIDS-defining criteria = CD4 <200 cells/mm³ OR

opportunistic infection/malignancy.

Hepatitis A, B, C, D, E Reviewer
Definition
Hepatitis = inflammation of the liver, commonly caused by viral infections (HAV, HBV, HCV,
HDV, HEV). It leads to hepatocellular injury, impaired liver function, and systemic
manifestations.

1. Hepatitis A (HAV)
●​ Cause: Hepatitis A virus (Picornavirus, RNA).​
 ●​ Transmission: Fecal-oral (contaminated food/water, poor sanitation).​

●​ Risk Factors: Poor hygiene, overcrowding, contaminated water/food.​

●​ Incubation: 2–6 weeks.​

●​ Clinical Manifestations:​

○​ Often mild, self-limiting​

○​ Fever, malaise, anorexia, nausea, vomiting, abdominal pain​

○​ Jaundice, dark urine, pale stools​

●​ Diagnostics: Anti-HAV IgM (acute), Anti-HAV IgG (past infection/immunity).​

●​ Complications: Rarely fulminant hepatitis, no chronic carrier state.​

●​ Prevention: HAV vaccine, hand hygiene, safe water supply.​

●​ Management: Supportive (rest, hydration, nutrition). No chronic treatment needed.

2. Hepatitis B (HBV)
●​ Cause: Hepatitis B virus (Hepadnavirus, DNA).​

●​ Transmission: Bloodborne, sexual contact, perinatal (mother-to-child).​

●​ Risk Factors: IV drug use, unprotected sex, healthcare exposure, blood

transfusions.​

●​ Incubation: 1–4 months.​

●​ Clinical Manifestations:​

○​ Asymptomatic to severe acute illness​

○​ Fever, fatigue, nausea, RUQ pain​

○​ Jaundice, hepatomegaly, dark urine​

●​ Diagnostics:​

○​ HBsAg (surface antigen = infection)​

○​ Anti-HBs (antibody = immunity)​

○​ Anti-HBc IgM (acute infection)​

○​ HBeAg (high infectivity).​

●​ Complications: Chronic hepatitis, cirrhosis, hepatocellular carcinoma.​

 ●​ Prevention: HBV vaccine, safe sex, avoid needle sharing, screen blood.​

●​ Management:​

○​ Acute: supportive​

○​ Chronic: antivirals (tenofovir, entecavir, lamivudine, interferon).​

3. Hepatitis C (HCV)
●​ Cause: Hepatitis C virus (Flavivirus, RNA).​

●​ Transmission: Bloodborne (IV drugs, transfusions before 1992, needle sticks).

Rarely sexual or perinatal.​

●​ Risk Factors: IV drug use, hemodialysis, multiple transfusions, organ transplant

before 1992.​

●​ Incubation: 2–12 weeks.​

●​ Clinical Manifestations:​

○​ Often asymptomatic initially​

○​ Fatigue, malaise, mild RUQ pain, nausea​

○​ May progress silently to chronic hepatitis.​

●​ Diagnostics: Anti-HCV antibody, HCV RNA (PCR for viral load).​

●​ Complications: High risk of chronic hepatitis (70–85%), cirrhosis, hepatocellular

carcinoma.​

●​ Prevention: No vaccine, avoid sharing needles, safe blood supply.​

●​ Management: Direct-acting antivirals (DAAs: sofosbuvir, ledipasvir, glecaprevir) →

high cure rates.​

4. Hepatitis D (HDV)
●​ Cause: Defective RNA virus requiring HBV (HBsAg) for replication.​

●​ Transmission: Same as HBV (blood, sexual, perinatal).​

●​ Risk Factors: HBV carriers, IV drug use.​

●​ Incubation: 2–8 weeks (with HBV).​

●​ Clinical Manifestations:​
 ○​ Co-infection with HBV: severe acute hepatitis​

○​ Superinfection in HBV carriers: rapid progression to cirrhosis.​

●​ Diagnostics: Anti-HDV, HDV RNA.​

●​ Complications: Accelerated cirrhosis, fulminant hepatitis.​

●​ Prevention: HBV vaccination prevents HDV.​

●​ Management: Interferon-alpha (limited efficacy). No specific antiviral.​

5. Hepatitis E (HEV)
●​ Cause: Hepatitis E virus (Hepevirus, RNA).​

●​ Transmission: Fecal-oral (contaminated water, undercooked pork/wild game).​

●​ Risk Factors: Poor sanitation, endemic areas (Asia, Africa, Middle East).​

●​ Incubation: 2–8 weeks.​

●​ Clinical Manifestations:​

○​ Acute self-limiting illness, similar to HAV​

○​ Jaundice, anorexia, fever, abdominal pain​

○​ Pregnant women: severe disease, fulminant hepatitis, high maternal

mortality.​

●​ Diagnostics: Anti-HEV IgM, HEV RNA.​

●​ Complications: Rarely chronic (except immunocompromised).​

●​ Prevention: Clean water, good sanitation, avoid undercooked meat. HEV vaccine
(limited availability in China).​

●​ Management: Supportive, ribavirin in chronic cases.​

Comparison Summary Table

Type Transmission Chronic? Prevention Complications

HAV Fecal-oral ❌ No Vaccine,

hygiene
Rare, fulminant

HBV Blood, sex,

perinatal
✅ Yes Vaccine Cirrhosis, HCC

HCV Blood (IV drugs,

transfusion)
✅ Yes No vaccine Cirrhosis, HCC

HDV Blood, needs

HBV
✅ Yes HBV vaccine Accelerated
cirrhosis

HEV Fecal-oral
(water, food)
❌ (except
immunocompro
Hygiene, water
safety
Fulminant in
pregnancy
mised)

📖 Pelvic Inflammatory Disease (PID) –

Nursing Reviewer
📝 Definition
Pelvic Inflammatory Disease (PID) is an infection and inflammation of the female upper
genital tract (uterus, fallopian tubes, ovaries, and surrounding pelvic structures). It usually
results from the ascending spread of microorganisms from the vagina and cervix.

⚠️ Causes & Risk Factors

●​ Common causative organi[Link]

○​ Neisseria gonorrhoeae (gonorrhea)​

○​ Chlamydia trachomatis (chlamydia)​

○​ Anaerobic bacteria, Mycoplasma, Ureaplasma​

 ●​ Risk factors:​

○​ Multiple sexual partners​

○​ Unprotected sexual intercourse​

○​ Previous history of STIs or PID​

○​ Young age at first intercourse (<25 years)​

○​ Intrauterine device (IUD) use (esp. within first 3 weeks)​

○​ Douching (alters vaginal flora)​

🩺 Pathophysiology
1.​ Pathogens enter the vagina → cervix → uterus → fallopian tubes → ovaries.​

2.​ Inflammation causes edema, exudate, adhesions, and scarring.​

3.​ Long-term → tubal obstruction, infertility, ectopic pregnancy, chronic pelvic pain.​

📍 Clinical Manifestations
●​ Lower abdominal or pelvic pain (most common)​

●​ Abnormal vaginal discharge (foul-smelling, purulent)​

●​ Dyspareunia (painful intercourse)​

●​ Dysuria​

●​ Irregular menstrual bleeding​

●​ Fever, chills​

●​ Cervical motion tenderness (“Chandelier sign”)​

●​ Nausea, vomiting (in severe cases)​

🔬 Diagnostic Tests
●​ History & physical exam (pelvic exam → tenderness)​

●​ Laboratory:​

○​ Cervical cultures (for gonorrhea, chlamydia)​

 ○​ CBC → ↑ WBC​

○​ ESR/CRP → elevated (inflammation)​

○​ Urinalysis (to rule out UTI)​

●​ Imaging:​

○​ Pelvic ultrasound (abscess, tubo-ovarian mass)​

●​ Laparoscopy (gold standard if diagnosis uncertain)​

💊 Medical Management
●​ Antibiotic therapy (broad-spectrum, covering gonorrhea and chlamydia):​

○​ Ceftriaxone IM + Doxycycline PO ± Metronidazole PO​

●​ Pain management – NSAIDs, analgesics​

●​ IV fluids if severe infection/dehydration​

●​ Hospitalization if:​

○​ Pregnant​

○​ Severe illness or abscess​

○​ Cannot tolerate PO meds​

●​ Surgery (rare) – drainage of abscess, hysterectomy (severe recurrent cases)​

🧑‍⚕️ Nursing Interventions

●​ Monitor vital signs, pain, vaginal discharge​

●​ Administer antibiotics as ordered​

●​ Provide analgesics, antipyretics​

●​ Encourage bed rest & hydration​

●​ Educate patient:​

○​ Complete full course of antibiotics​

○​ Avoid sexual intercourse until treatment is complete​

○​ Use condoms to prevent recurrence​

 ○​ Encourage partner treatment to prevent reinfection​

●​ Psychological support (address stigma, anxiety, fertility concerns)​

🚨 Complications
●​ Infertility (due to scarring of fallopian tubes)​

●​ Ectopic pregnancy​

●​ Chronic pelvic pain​

●​ Peritonitis, sepsis (if untreated)​

●​ Tubo-ovarian abscess​

✅ Quick Mnemonic: “PID = PAIN”

●​ P – Pelvic pain​

●​ A – Abnormal discharge/bleeding​

●​ I – Infertility risk​

●​ N – Nausea, fever, tenderness​

📘 Benign Prostatic Hyperplasia (BPH)

📖 Definition
●​ Noncancerous enlargement of the prostate gland commonly seen in aging men.​

●​ Caused by hyperplasia of prostatic stromal and epithelial cells, leading to urinary

outflow obstruction.​

🧬 Pathophysiology
1.​ Aging → ↓ apoptosis + hormonal changes (↑ DHT from testosterone).​

2.​ Prostate cells proliferate, enlarging prostate (especially periurethral region).​

3.​ Compression of urethra → bladder outlet obstruction → urinary retention.​

4.​ Long-term obstruction → bladder hypertrophy, diverticula, hydronephrosis, renal

impairment.​
⚠️ Risk Factors
●​ Age: >50 years old.​

●​ Hormonal changes: Increased DHT.​

●​ Family history.​

●​ Lifestyle: Obesity, physical inactivity.​

●​ Comorbidities: Diabetes, cardiovascular disease.​

🩺 Clinical Manifestations
Lower Urinary Tract Symptoms (LUTS):

●​ Voiding (Obstructive):​

○​ Weak stream​

○​ Hesitancy, straining​

○​ Incomplete bladder emptying​

○​ Intermittency (stopping and starting)​

●​ Storage (Irritative):​

○​ Nocturia (frequent night urination)​

○​ Urgency, frequency​

○​ Dysuria (painful urination)​

🧪 Diagnostic Tests
●​ Digital Rectal Exam (DRE): Enlarged, smooth, rubbery prostate.​

●​ Prostate-Specific Antigen (PSA): Elevated (rule out prostate cancer).​

●​ Urinalysis: Rule out infection.​

●​ Serum creatinine/BUN: Evaluate kidney function.​

●​ Ultrasound (transrectal or renal/bladder): Assess size & residual urine.​

●​ Uroflowmetry: Measures urine flow rate.​

💊 Medical Management
●​ Lifestyle modification: Avoid caffeine, alcohol, evening fluid intake.​

●​ Medications:​

○​ Alpha-adrenergic blockers (tamsulosin, doxazosin): Relax smooth muscle

→ improve urine flow.​

○​ 5-alpha reductase inhibitors (finasteride, dutasteride): Shrink prostate by

blocking testosterone → DHT conversion.​

○​ Combination therapy for severe symptoms.​

Tamsulosin - relax smooth muscles

Finasteride - shrink prostate

🛠️ Surgical Management
●​ TURP (Transurethral Resection of Prostate): Gold standard, removes prostate
tissue.​

●​ TUIP (Transurethral Incision of Prostate): Small prostate cases.​

●​ Laser therapy: Minimally invasive.​

●​ Prostatectomy: Open surgery for very large prostates.​

●​ Prostatic stents: In high-risk patients unfit for surgery.​

🧑‍⚕️ Nursing Interventions

●​ Assess urinary symptoms & monitor for retention.​

●​ Encourage timed voiding & double voiding technique.​

●​ Maintain hydration but restrict evening fluids to reduce nocturia.​

●​ Educate on avoiding bladder irritants (caffeine, alcohol, spicy foods).​

●​ Monitor for post-op complications if TURP:​

○​ Hematuria​

○​ TURP syndrome (hyponatremia from irrigation fluid absorption)​

○​ Catheter blockage/clot retention​

 ●​ Provide catheter care: Continuous bladder irrigation (CBI) post-TURP to prevent clot
retention.

TURP SYNDROME - HYPONATREMIA​

✅ Quick Mnemonic: "BPH – BE PROSTATE HEALTHY"

●​ Bladder training​

●​ Prostate meds (alpha-blockers, 5-ARIs)​

●​ Hydration & lifestyle management​

📘 Appendicitis Reviewer
🔹 Definition
Appendicitis is the inflammation of the vermiform appendix, usually caused by
obstruction of the appendiceal lumen. It is one of the most common surgical emergencies.

🔹 Etiology / Causes
●​ Luminal obstruction (most common cause) due to:​

○​ Fecalith (hard stool)​

○​ Lymphoid hyperplasia (common in children/adolescents)​

○​ Tumors​

○​ Parasites (rare)​

●​ Bacterial invasion follows obstruction, leading to inflammation, edema, ischemia, and

possible perforation.​

🔹 Risk Factors
●​ Age: Most common in 10–30 years​

●​ Family history of appendicitis​

●​ Diet low in fiber, high in refined carbohydrates​

●​ Infections that cause lymphoid tissue hyperplasia​

🔹 Pathophysiology
1.​ Obstruction of appendix lumen → ↑ intraluminal pressure​

2.​ Mucosal secretions accumulate → ischemia develops​

3.​ Bacterial overgrowth → inflammation & edema​

4.​ Untreated: necrosis → perforation → peritonitis​

🔹 Clinical Manifestations
●​ Classic signs:​

○​ Initial periumbilical pain → later shifts to RLQ (McBurney’s point)​

○​ Anorexia, nausea, vomiting​

○​ Low-grade fever​

●​ Physical exam findings:​

○​ Tenderness at McBurney’s point​

○​ Rebound tenderness (Blumberg’s sign)​

○​ Rovsing’s sign: RLQ pain when LLQ is palpated​

○​ Psoas sign: pain with hip extension (retrocecal appendix)​

○​ Obturator sign: pain with internal rotation of flexed right thigh (pelvic
appendix)​

🔹 Complications
●​ Perforation → peritonitis​

●​ Abscess formation​

●​ Sepsis​

🔹 Diagnostic Tests
●​ Laboratory:​

○​ CBC → ↑ WBC count with neutrophilia​

 ○​ CRP elevated​

●​ Imaging:​

○​ Abdominal ultrasound → enlarged, non-compressible appendix​

○​ CT scan (gold standard in adults)​

●​ Urinalysis to rule out UTI/kidney stones​

🔹 Medical & Surgical Management

●​ Preoperative:​

○​ NPO, IV fluids, analgesics, antibiotics​

○​ Avoid laxatives & enemas (can cause perforation)​

○​ Avoid applying heat on abdomen​

●​ Surgical:​

○​ Appendectomy (open or laparoscopic) – definitive treatment​

●​ Postoperative:​

○​ IV antibiotics (if perforation)​

○​ Pain management​

○​ Early ambulation​

○​ Monitor for infection​

🔹 Nursing Interventions
●​ Assessment: Monitor pain, fever, abdominal rigidity, bowel sounds​

●​ Pre-op care:​

○​ Maintain NPO​

○​ Administer fluids & antibiotics​

○​ Provide comfort measures (position: semi-Fowler’s for drainage if ruptured)​

●​ Post-op care:​

○​ Monitor VS, wound, drains​

 ○​ Encourage ambulation​

○​ Advance diet as tolerated​

○​ Teach wound care & infection signs​

✅If aKey NCLEX Tip:​

rupture/perforation (medical emergency). 🚨

patient with suspected appendicitis suddenly reports relief from pain → suspect

Peritonitis Reviewer
Definition
Peritonitis is the inflammation of the peritoneum, the serous membrane lining the
abdominal cavity and covering the visceral organs. It is usually caused by bacterial
infection, either from rupture of abdominal organs or via the bloodstream.

Etiology / Causes
●​ Primary peritonitis – spontaneous bacterial infection (often in patients with ascites,
liver cirrhosis).​

●​ Secondary peritonitis – most common, due to perforation or rupture:​

○​ Perforated appendix​

○​ Perforated peptic ulcer​

○​ Diverticulitis​

○​ Bowel obstruction with perforation​

○​ Trauma / stab wounds​

○​ Perforated gallbladder​

●​ Tertiary peritonitis – persistent or recurrent infection despite treatment (often in

immunocompromised).​

Risk Factors
●​ Abdominal surgery​

●​ Perforated peptic ulcer or appendix​

●​ Trauma to the abdomen​

●​ Diverticulitis​
 ●​ Peritoneal dialysis​

●​ Liver disease with ascites​

Pathophysiology
1.​ Bacterial contamination of peritoneal cavity (rupture/perforation).​

2.​ Inflammatory response → exudation of fluid, fibrin, and leukocytes.​

3.​ Fluid shifts into the peritoneal space (“third spacing”) → hypovolemia & shock.​

4.​ Paralytic ileus develops due to peritoneal irritation.​

5.​ Sepsis and multi-organ failure if untreated.​

Clinical Manifestations
●​ Severe abdominal pain (sudden, diffuse, worsens with movement)​

●​ Abdominal rigidity & board-like abdomen​

●​ Rebound tenderness​

●​ Abdominal distention​

●​ Nausea and vomiting​

●​ Fever, chills​

●​ Tachycardia, tachypnea​

●​ Oliguria (due to hypovolemia/shock)​

●​ Restlessness, anxiety​

Complications
●​ Sepsis → septic shock​

●​ Abscess formation​

●​ Hypovolemic shock​

●​ Paralytic ileus​

●​ Multi-organ failure​

Diagnostic Tests
 ●​ CBC – ↑ WBC (leukocytosis)​

●​ Blood cultures – identify causative organism​

●​ Electrolytes – may show imbalances from vomiting/third spacing​

●​ Abdominal x-ray – free air (if perforation), dilated loops of bowel​

●​ Ultrasound / CT scan – abscess, fluid collection​

●​ Paracentesis – fluid analysis (WBCs, bacteria)​

Medical Management
●​ Emergency condition – treat underlying cause​

●​ NPO & IV fluids for fluid replacement​

●​ Broad-spectrum IV antibiotics (cephalosporins, aminoglycosides, metronidazole)​

●​ NG tube insertion – decompress bowel​

●​ Analgesics for pain​

●​ Oxygen therapy if hypoxemia​

●​ Surgery (exploratory laparotomy/laparoscopy) – repair perforation, drain abscess,

lavage peritoneum​

Nursing Interventions
●​ Assessment: Monitor VS (watch for shock – tachycardia, hypotension).​

●​ Pain management: Administer analgesics as prescribed.​

●​ Positioning: Semi-Fowler’s to localize infection in pelvis and ease breathing.​

●​ Fluid balance: Strict I&O, monitor urine output.​

●​ Nutrition: Maintain NPO, give parenteral nutrition if prolonged NPO.​

●​ Infection control: Administer antibiotics, monitor for fever & WBC changes.​

●​ Post-op care: Wound/ drain care, prevent infection.​

●​ Patient education: Report worsening abdominal pain, fever, chills.​

✅ Key Nursing Alert:​

If a patient with sudden severe abdominal pain + rigid board-like abdomen → suspect
peritonitis (surgical emergency).
Cystitis (Urinary Bladder Infection)
Definition
●​ Inflammation of the urinary bladder, usually caused by bacterial infection (most
commonly Escherichia coli).​

●​ Considered a lower urinary tract infection (UTI).​

Pathophysiology
1.​ Bacteria (often from the perineum/rectal flora) enter the urethra.​

2.​ Pathogens ascend into the bladder, adhering to urothelial lining.​

3.​ Inflammatory response leads to: edema, hyperemia, and infiltration of leukocytes.​

4.​ If untreated, can ascend to the ureters and kidneys → pyelonephritis.​

Risk Factors
●​ Female gender (short urethra, proximity to anus).​

●​ Sexual intercourse ("honeymoon cystitis").​

●​ Poor perineal hygiene.​

●​ Use of urinary catheters.​

●​ Diabetes mellitus.​

●​ Pregnancy.​

●​ Postmenopausal changes.​

●​ Urinary obstruction (e.g., stones, BPH).​

Clinical Manifestations
●​ Lower urinary tract symptoms (LUTS):​

○​ Dysuria (burning sensation on urination).​

○​ Urinary frequency and urgency.​

○​ Suprapubic pain or pressure.​

○​ Hematuria (blood-tinged urine).​

 ○​ Cloudy or foul-smelling urine.​

●​ In elderly: confusion, agitation, or new-onset incontinence may occur.​

Diagnostic Tests
●​ Urinalysis: pyuria (WBCs), bacteriuria, hematuria, nitrites (if gram-negative).​

●​ Urine culture and sensitivity: to identify causative organism.​

●​ CBC: leukocytosis if infection is severe.​

●​ Ultrasound/CT scan: in recurrent or complicated cases.​

Medical Management
●​ Antibiotics:​

○​ Trimethoprim-sulfamethoxazole (TMP-SMX).​

○​ Nitrofurantoin.​

○​ Fosfomycin.​

○​ Fluoroquinolones (reserved for complicated cases).​

●​ Phenazopyridine: urinary analgesic (causes orange-colored urine).​

●​ Increase oral fluids (2–3 L/day if not contraindicated).​

●​ Cranberry juice: may reduce bacterial adhesion (preventive, not curative).​

Nursing Management / Interventions

●​ Encourage fluid intake to flush bacteria.​

●​ Teach proper perineal hygiene (wipe front to back).​

●​ Encourage voiding every 2–3 hours and after intercourse.​

●​ Administer prescribed antibiotics and stress adherence to regimen.​

●​ Use heating pad to relieve suprapubic pain.​

●​ Educate about avoiding irritants: caffeine, alcohol, carbonated drinks, and

perfumed hygiene products.​

●​ For catheterized patients: maintain sterile technique and closed drainage system.​
Cholecystitis Reviewer
Definition
Cholecystitis is the inflammation of the gallbladder, usually caused by obstruction of the
cystic duct by gallstones (calculous cholecystitis) or, less commonly, without stones
(acalculous cholecystitis).

Types
1.​ Acute Cholecystitis​

○​ Sudden inflammation, usually due to gallstone obstruction.​

○​ Can lead to empyema, gangrene, or perforation.​

2.​ Chronic Cholecystitis​

○​ Recurrent or prolonged inflammation.​

○​ Gallbladder becomes fibrotic and contracted.​

Pathophysiology
●​ Gallstone lodges in cystic duct → bile stasis → distension of gallbladder →
inflammation → ischemia & possible necrosis.​

●​ In acalculous cholecystitis: hypoperfusion, bile stasis, infection (commonly in critically

ill patients).​

Risk Factors
●​ Female, age >40 years​

●​ Obesity, rapid weight loss​

●​ Pregnancy (estrogen increases cholesterol in bile)​

●​ High-fat diet​

●​ Family history of gallstones​

●​ Prolonged fasting or total parenteral nutrition​

●​ Diabetes mellitus​
Clinical Manifestations
●​ Pain: Sudden, severe, steady pain in right upper quadrant (RUQ) or epigastrium;
may radiate to right shoulder or scapula.​

●​ Murphy’s sign: Inspiratory arrest upon deep palpation of RUQ.​

●​ Fever, chills​

●​ Nausea, vomiting, indigestion​

●​ Abdominal tenderness, guarding​

●​ Jaundice (if common bile duct obstructed)​

●​ Dark urine, clay-colored stools (bile obstruction)​

Complications
●​ Gallbladder gangrene, perforation​

●​ Empyema (pus in gallbladder)​

●​ Peritonitis​

●​ Biliary obstruction → cholangitis, pancreatitis​

Diagnostic Tests
●​ Ultrasound – first-line, shows gallstones and gallbladder wall thickening.​

●​ HIDA scan (hepatobiliary iminodiacetic acid scan) – assesses cystic duct

obstruction.​

●​ CT or MRI – complications, alternative imaging.​

●​ Blood tests:​

○​ ↑ WBC (infection/inflammation)​

○​ ↑ Liver enzymes (AST, ALT, ALP)​

○​ ↑ Bilirubin (if obstruction)​

○​ ↑ Amylase/lipase (if pancreatitis)​

Medical Management
 ●​ Initial treatment:​

○​ NPO (rest gallbladder)​

○​ IV fluids​

○​ Analgesics (NSAIDs, opioids)​

○​ IV antibiotics​

○​ Antiemetics​

●​ Definitive treatment:​

○​ Laparoscopic cholecystectomy (gold standard).​

○​ Open cholecystectomy if severe inflammation or complications.​

●​ Percutaneous cholecystostomy (in high-risk surgical patients).​

Nursing Interventions
1.​ Pain management​

○​ Administer prescribed analgesics.​

○​ Position patient for comfort (Fowler’s or semi-Fowler’s).​

2.​ Monitor GI symptoms​

○​ Assess for nausea, vomiting, jaundice, stool/urine changes.​

3.​ NPO initially​

○​ Progress to low-fat diet as tolerated.​

4.​ Monitor for complications​

○​ Peritonitis: abdominal rigidity, rebound tenderness, fever.​

○​ Sepsis: hypotension, tachycardia.​

5.​ Postoperative care​

○​ Encourage early ambulation after laparoscopic surgery.​

○​ Teach incision site care.​

○​ Advise lifelong low-fat diet after gallbladder removal.​

6.​ Patient education​

 ○​ Avoid fatty, fried foods.​

○​ Maintain healthy weight.​

○​ Recognize symptoms of recurrence or complications.​

✅Female,
Mnemonic for Cholecystitis Risk Factors (the 4 F’s):​
Forty, Fat, Fertile

Crohn’s Disease Reviewer

Definition
●​ A chronic inflammatory bowel disease (IBD) that can affect any part of the
gastrointestinal (GI) tract, from the mouth to anus.​

●​ Characterized by transmural inflammation (extends through all layers of the bowel

wall).​

●​ Often presents with skip lesions (patchy areas of inflammation).​

Etiology & Risk Factors

●​ Exact cause unknown (idiopathic).​

●​ Believed to result from:​

○​ Immune system dysfunction (overactive immune response to gut bacteria).​

○​ Genetic predisposition (family history).​

○​ Environmental factors (smoking, diet high in fat/refined sugar, NSAID use).​

●​ More common in young adults (15–35 years).​

Pathophysiology
1.​ Trigger (genetic + environmental factors) → abnormal immune response.​

2.​ Inflammation of the intestinal wall (transmural, patchy).​

3.​ Development of ulcers, granulomas, strictures, and fistulas.​

4.​ Malabsorption and narrowing of lumen.​

5.​ Chronic relapsing-remitting course → periods of flare-ups and remissions.​

Clinical Manifestations
●​ GI Symptoms:​

○​ Persistent diarrhea (often bloody or with mucus).​

○​ Abdominal pain (usually in right lower quadrant).​

○​ Weight loss, malnutrition.​

○​ Fever, fatigue.​

○​ Tenesmus (feeling of incomplete bowel evacuation).​

●​ Complications:​

○​ Intestinal obstruction (due to strictures).​

○​ Fistulas (abnormal connections between bowel and other organs).​

○​ Abscess formation.​

○​ Perforation & peritonitis.​

○​ Colon cancer risk.​

●​ Extraintestinal Symptoms:​

○​ Arthritis, uveitis (eye inflammation), skin lesions (erythema nodosum), liver

disease.​

Diagnostic Tests
●​ Laboratory:​

○​ CBC → anemia (due to blood loss), ↑ WBC (infection/inflammation).​

○​ CRP & ESR → elevated (inflammation).​

○​ Electrolytes → imbalances from diarrhea.​

●​ Stool tests: blood, WBCs, pathogens.​

●​ Endoscopy/Colonoscopy: shows skip lesions, cobblestone appearance, ulcers.​

●​ Biopsy: confirms transmural inflammation, granulomas.​

●​ Imaging: CT/MRI enterography → fistulas, abscesses, strictures.​

Medical Management
 ●​ Medications:​

○​ Aminosalicylates (5-ASA): sulfasalazine, mesalamine (reduce

inflammation).​

○​ Corticosteroids: prednisone (acute flares).​

○​ Immunosuppressants: azathioprine, methotrexate.​

○​ Biologics (anti-TNF agents): infliximab, adalimumab.​

○​ Antibiotics: metronidazole (for abscess/fistula).​

●​ Nutritional Therapy:​

○​ High-calorie, high-protein, low-fiber diet during flares.​

○​ Vitamin and iron supplements.​

○​ Avoid trigger foods (dairy, fatty, spicy foods).​

●​ Surgical Management:​

○​ Reserved for complications (strictures, abscess, perforation).​

○​ Bowel resection → not curative (disease often recurs at other sites).​

Nursing Interventions
1.​ Monitor GI symptoms: stool output, blood in stool, pain.​

2.​ Maintain fluid & electrolyte balance: monitor I&O, IV fluids, oral rehydration.​

3.​ Nutritional support: small frequent meals, avoid high-residue foods during flare.​

4.​ Promote rest: reduce stress, energy conservation.​

5.​ Pain management: prescribed analgesics.​

6.​ Prevent complications: monitor for signs of perforation (rigid abdomen, severe
pain, fever).​

7.​ Patient education:​

○​ Adherence to medications.​

○​ Diet modifications.​

○​ Smoking cessation.​

○​ Stress management techniques.​

✅ Key NCLEX Points:
●​ Crohn’s = transmural, skip lesions, cobblestone appearance.​

●​ At risk for fistulas, strictures, obstruction.​

●​ Diet: low-fiber during flare-ups, high-protein/calorie overall.​

●​ Surgery is not curative (unlike ulcerative colitis).​

Ulcerative Colitis (UC) – Reviewer

📌 Definition
Ulcerative Colitis is a chronic, idiopathic inflammatory bowel disease (IBD) that causes
continuous inflammation and ulceration of the colon and rectum, beginning in the
rectum and extending proximally in a continuous manner. Unlike Crohn’s disease, it affects
only the mucosa and submucosa (superficial layers) of the colon.

📌 Pathophysiology
1.​ Immune dysregulation → inappropriate activation of immune cells in the intestinal
mucosa.​

2.​ Inflammation of colonic mucosa → continuous ulceration starting from the rectum.​

3.​ Ulcer formation → bleeding, pus, and mucus production.​

4.​ Mucosal damage → impaired absorption → diarrhea & electrolyte imbalance.​

5.​ Severe cases → toxic megacolon or colon perforation.​

📌 Risk Factors
●​ Family history of IBD​

●​ Caucasians & Ashkenazi Jews​

●​ Onset usually between 15–35 years​

●​ Environmental factors: diet (low fiber, high fat), pollution, stress​

●​ Overactive immune response​

📌 Clinical Manifestations
 ●​ Hallmark: Bloody diarrhea with mucus​

●​ Abdominal cramping (especially lower left quadrant)​

●​ Tenesmus (feeling of incomplete evacuation)​

●​ Urgency & frequent stools​

●​ Fatigue, weight loss, anorexia​

●​ Low-grade fever (severe cases)​

●​ Extraintestinal manifestations: arthritis, uveitis, erythema nodosum, primary

sclerosing cholangitis​

📌 Complications
●​ Toxic megacolon (life-threatening dilation of colon)​

●​ Perforation → peritonitis​

●​ Severe hemorrhage → anemia​

●​ Increased risk of colorectal cancer​

●​ Malabsorption → fluid & electrolyte imbalance​

📌 Diagnostic Tests
●​ Colonoscopy with biopsy (definitive) → continuous mucosal ulceration​

●​ Barium enema → “lead pipe appearance” (loss of haustra)​

●​ CBC → anemia, leukocytosis​

●​ ESR/CRP → elevated (inflammation)​

●​ Stool exam → rule out infection​

📌 Medical Management
Goals: reduce inflammation, control symptoms, prevent complications
1.​ Pharmacologic:​

○​ Aminosalicylates (5-ASA): Sulfasalazine, Mesalamine (↓ inflammation)​

○​ Corticosteroids: Prednisone (for flare-ups)​

 ○​ Immunosuppressants: Azathioprine, Cyclosporine​

○​ Biologics: Infliximab, Adalimumab (anti-TNF agents)​

○​ Antidiarrheals: Loperamide (cautiously used)​

2.​ Surgical:​

○​ Indicated if severe, unresponsive, or complications occur.​

○​ Proctocolectomy with ileostomy (curative).​

○​ Ileoanal anastomosis (J-pouch surgery) → avoids permanent stoma.​

3.​ Dietary & Lifestyle:​

○​ High-calorie, high-protein diet​

○​ Low-residue diet during flare-ups (avoid high-fiber, spicy, fatty foods)​

○​ Small, frequent meals​

○​ Adequate fluids & electrolytes​

○​ Avoid caffeine, alcohol, dairy if intolerant​

📌 Nursing Interventions
●​ Monitor stool (frequency, amount, blood, mucus)​

●​ Administer prescribed medications (anti-inflammatory, steroids,

immunosuppressants)​

●​ Maintain fluid & electrolyte balance (IV fluids if severe diarrhea)​

●​ Provide nutritional support (high-calorie, low-residue diet)​

●​ Encourage rest during flare-ups​

●​ Monitor for signs of toxic megacolon (abdominal distention, fever, tachycardia)​

●​ Provide psychological support (chronic disease management, coping with possible

stoma)​

●​ Educate on smoking cessation, stress reduction, regular screenings for colon

cancer​

✅ Mnemonics
Ulcerative Colitis – “COLITIS”
 ●​ C – Colon inflammation (continuous, rectum → proximal)​

●​ O – Oozing blood & mucus in stool​

●​ L – Low-grade fever, Left lower quadrant pain​

●​ I – Increased risk of colon cancer​

●​ T – Tenesmus & Toxic megacolon risk​

●​ I – Inflammation of only mucosa & submucosa​

●​ S – Systemic symptoms (arthritis, uveitis, skin lesions)​

Urolithiasis (Urinary Tract Stones /

Kidney Stones)
Definition
●​ Urolithiasis is the formation of stones (calculi) in the urinary tract, which may occur
in the kidney (nephrolithiasis), ureter (ureterolithiasis), or bladder (cystolithiasis).​

●​ Stones are usually composed of calcium oxalate, calcium phosphate, uric acid,
struvite, or cystine.​

Pathophysiology
1.​ Supersaturation of urine with stone-forming substances (calcium, oxalate, uric acid,
etc.).​

2.​ Crystallization and aggregation of these salts.​

3.​ Crystal retention in the urinary tract.​

4.​ Leads to stone formation → obstruction → urinary stasis → pain and possible
infection.​

Risk Factors
●​ Dehydration (low fluid intake).​

●​ Diet high in oxalate, sodium, animal protein.​

●​ Hyperparathyroidism → increased calcium.​

●​ Recurrent urinary tract infections (esp. Proteus → struvite stones).​

 ●​ Family history of stones.​

●​ Gout (uric acid stones).​

●​ Prolonged immobilization (bone resorption).​

Clinical Manifestations
●​ Renal colic: severe flank pain radiating to the groin (classic).​

●​ Hematuria (blood in urine).​

●​ Nausea and vomiting.​

●​ Urinary urgency, frequency, or dysuria (if stone near bladder/urethra).​

●​ Oliguria or anuria (if complete obstruction).​

●​ Signs of infection: fever, chills (if complicated by UTI).​

Diagnostic Tests
●​ Urinalysis: hematuria, crystals, infection.​

●​ KUB X-ray: may detect radiopaque stones (calcium).​

●​ CT scan (non-contrast): gold standard for detecting stones.​

●​ Ultrasound: detects hydronephrosis, useful in pregnant patients.​

●​ IV Pyelogram (IVP): visualizes obstruction.​

●​ Stone analysis: determines type of stone for prevention.​

Medical & Surgical Management

Medical Management

●​ Pain control: NSAIDs, opioids.​

●​ Hydration: IV fluids to flush stone (if not obstructed).​

●​ Medications:​

○​ α-blockers (tamsulosin) → relax ureter, aid passage.​

○​ Allopurinol → uric acid stones.​

○​ Thiazide diuretics → reduce calcium stones.​

 ●​ Antibiotics if UTI present.​

Surgical Management (if stone does not pass spontaneously, usually >5–7 mm):

●​ Extracorporeal Shock Wave Lithotripsy (ESWL): non-invasive stone

fragmentation.​

●​ Ureteroscopy with stone extraction.​

●​ Percutaneous nephrolithotomy: for large or staghorn stones.​

●​ Open surgery (rare, last resort).​

Nursing Interventions
●​ Assess pain and administer prescribed analgesics.​

●​ Encourage increased fluid intake (3–4 L/day) unless contraindicated.​

●​ Strain urine to catch stones for analysis.​

●​ Monitor intake and output.​

●​ Educate on diet modifications based on stone type:​

○​ Calcium oxalate → avoid spinach, nuts, chocolate, tea.​

○​ Uric acid → reduce red meat, organ meats, shellfish.​

○​ Struvite → treat underlying infection.​

●​ Provide teaching on lifestyle changes: hydration, balanced diet, activity.​

Pancreatitis Reviewer
Definition
●​ Pancreatitis: Inflammation of the pancreas caused by premature activation of
digestive enzymes inside the pancreas, leading to autodigestion, tissue injury,
and possible systemic complications.​

●​ Can be acute (sudden, reversible if treated) or chronic (progressive, irreversible

damage).​

Types
1.​ Acute Pancreatitis​
 ○​ Sudden inflammation, usually resolves with treatment.​

○​ Causes: Gallstones, alcohol, hypertriglyceridemia, drugs, trauma, infections.​

2.​ Chronic Pancreatitis​

○​ Long-term inflammation → fibrosis, pancreatic insufficiency, and irreversible

damage.​

○​ Causes: Chronic alcohol use, genetic predisposition, autoimmune disorders.​

Etiology / Risk Factors

●​ Gallstones (most common cause of acute)​

●​ Alcohol abuse (most common cause of chronic)​

●​ Hypertriglyceridemia (>1000 mg/dL)​

●​ Hypercalcemia​

●​ Abdominal trauma or surgery​

●​ Certain drugs (azathioprine, thiazides, valproic acid, corticosteroids)​

●​ Viral infections (mumps, coxsackievirus)​

●​ Autoimmune diseases​

●​ ERCP (endoscopic retrograde cholangiopancreatography) complications​

Pathophysiology
1.​ Obstruction (gallstones) or direct injury (alcohol, trauma) → premature activation of
trypsinogen → trypsin inside pancreas.​

2.​ Trypsin activates other enzymes (lipase, elastase) → autodigestion of pancreatic

tissue.​

3.​ Inflammation → necrosis, hemorrhage, and release of cytokines.​

4.​ Systemic inflammatory response → shock, multi-organ failure possible in severe

cases.​

Clinical Manifestations
●​ Abdominal pain: Severe, sudden, epigastric pain radiating to the back; worse
after meals or alcohol.​
 ●​ Nausea and vomiting​

●​ Fever, tachycardia, hypotension (systemic response)​

●​ Abdominal distention, decreased bowel sounds​

●​ Jaundice (if biliary obstruction present)​

●​ Cullen’s sign: Bluish periumbilical discoloration (internal bleeding)​

●​ Grey Turner’s sign: Flank bruising (retroperitoneal bleeding)​

●​ Chronic pancreatitis may present with:​

○​ Steatorrhea (fatty stools, foul-smelling)​

○​ Weight loss​

○​ Diabetes mellitus (due to islet cell destruction)​

Diagnostic Tests
●​ Blood tests:​

○​ ↑ Serum amylase (early, peaks within 24h)​

○​ ↑ Serum lipase (more specific, rises later, stays longer)​

○​ ↑ WBC count, ↑ CRP (inflammation)​

○​ ↑ Blood glucose​

○​ ↑ Bilirubin (if bile duct obstruction)​

●​ Imaging:​

○​ Ultrasound (gallstones)​

○​ CT scan (detect necrosis, abscess, pseudocyst)​

○​ ERCP (to visualize ducts; also therapeutic)​

Complications
●​ Local: Pseudocyst, abscess, necrosis, hemorrhage​

●​ Systemic: Shock, ARDS, renal failure, hypocalcemia (due to fat saponification), DIC,
sepsis, diabetes mellitus (chronic)​
Medical Management
●​ Acute Pancreatitis:​

○​ NPO (nothing by mouth) → bowel rest​

○​ IV fluids & electrolyte replacement (aggressive hydration)​

○​ Pain control: Opioids (morphine, hydromorphone)​

○​ NG tube for decompression if severe vomiting​

○​ Antibiotics (if infection suspected)​

○​ Treat underlying cause (ERCP for gallstones, triglyceride control, alcohol

cessation)​

●​ Chronic Pancreatitis:​

○​ Pancreatic enzyme replacement therapy (PERT)​

○​ Insulin therapy (if diabetes develops)​

○​ Low-fat diet, alcohol cessation​

○​ Surgery: Pancreatic drainage, resection, or stent placement​

Nursing Interventions
●​ Monitor vital signs (look for shock)​

●​ Strict NPO → progress to clear fluids as tolerated​

●​ Maintain IV hydration and electrolyte balance​

●​ Administer pain medications as ordered​

●​ Place in semi-Fowler’s or side-lying position (relieves pressure on pancreas)​

●​ Monitor for signs of hypocalcemia (Chvostek’s, Trousseau’s sign)​

●​ Monitor blood glucose → insulin therapy if needed​

●​ Educate on alcohol avoidance and low-fat diet​

●​ Monitor for complications: pseudocyst rupture, sepsis, respiratory distress​

✅ Quick Mnemonic: "I GET SMASHED" (Causes of Acute Pancreatitis)

●​ I – Idiopathic​
●​ G – Gallstones​

●​ E – Ethanol (alcohol)​

●​ T – Trauma​

●​ S – Steroids​

●​ M – Mumps (virus)​

●​ A – Autoimmune​

●​ S – Scorpion sting​

●​ H – Hyperlipidemia / Hypercalcemia​

●​ E – ERCP​

●​ D – Drugs​